Spontaneous Bacterial Peritonitis

On this page

Quick Reference

RxDrug of choiceCeftriaxone (1-2 g IV daily) or Cefotaxime (2 g IV q8h)

AltAlternativesCiprofloxacin (400 mg IV q12h), Meropenem (1 g IV q8h for nosocomial cases)

⊘AvoidDelayed antibiotic initiation while awaiting cultures; prolonged PPI use without indication

DxTest of choiceDiagnostic paracentesis with ascitic fluid ANC count

ScKey scoreMELD Score (≥ 22 indicates high mortality risk)

→When to referImmediately upon first diagnosis of SBP for liver transplant evaluation

SBP is a medical emergency; treat any ascitic ANC ≥ 250 cells/mm³ with immediate IV antibiotics and IV albumin to prevent fatal renal failure.

Spontaneous bacterial peritonitis (SBP) is a life-threatening infection of ascitic fluid occurring in patients with advanced cirrhosis without an identifiable intra-abdominal source. It is a hallmark of decompensated liver disease, driven by the translocation of gut bacteria across a compromised intestinal barrier into the peritoneal cavity. The diagnosis is defined by an ascitic fluid absolute neutrophil count (ANC) ≥ 250 cells/mm³, which mandates immediate empirical antibiotic therapy. SBP frequently precipitates acute-on-chronic liver failure (ACLF) and hepatorenal syndrome (HRS), with a 1-year mortality rate exceeding 60%. Management focuses on rapid antibiotic initiation, intravenous albumin for renal protection, and lifelong secondary prophylaxis to prevent the high rate of recurrence.

Overview and Recommendations

Background

•Spontaneous bacterial peritonitis (SBP) is defined as a monomicrobial infection of ascitic fluid in the absence of a surgically treatable source, representing a critical manifestation of decompensated . It accounts for approximately 2.5% of all cirrhosis-related hospitalizations and carries a 3-month mortality rate of 25%, often serving as a sentinel event that signals the need for evaluation.
•The central pathophysiology involves the 'gut-liver-immune axis' failure, where portal hypertension-induced intestinal dysbiosis and structural barrier disruption allow enteric organisms (most commonly and ) to translocate to mesenteric lymph nodes and seed the peritoneal space.
•Cirrhosis-associated immune dysfunction (CAID) further facilitates infection, as low complement levels and impaired phagocytic activity in the ascitic fluid fail to contain the bacterial challenge, leading to a profound systemic inflammatory response.
•Risk factors for SBP include ascitic fluid protein < 15 g/L (indicating low opsonic activity), serum bilirubin ≥ 3 mg/dL, and the use of (PPIs), which increase infection risk three-fold by facilitating bacterial overgrowth.
•Clinical variants include Culture-Negative Neutrocytic Ascites (CNNA), which presents with elevated neutrophils but negative cultures and requires identical treatment to classic SBP, and Monomicrobial Non-neutrocytic Bacterascites (MNB), which may represent early colonization.

Evaluation

•Suspect SBP in any patient with cirrhosis and who presents with fever, abdominal pain, or unexplained clinical deterioration, including new-onset or acute kidney injury (AKI). Maintain a high index of suspicion as the systemic inflammatory response is often blunted in end-stage liver disease, and many patients may be asymptomatic or 'silent.'
•Perform a diagnostic immediately upon hospital admission for all patients with cirrhosis and ascites, or whenever there is a change in clinical status; every hour of delay in paracentesis increases the risk of in-hospital mortality by 3.3%.
•Order an ascitic fluid analysis including a total cell count with differential, and inoculate 10 mL of fluid into aerobic and anaerobic blood culture bottles at the bedside to maximize diagnostic yield.
•Diagnose SBP when the ascitic fluid absolute neutrophil count (ANC) is ≥ 250 cells/mm³ (calculated as the total WBC count multiplied by the percentage of neutrophils), regardless of the culture result.
•Assess for secondary peritonitis (e.g., perforated viscus) if the ascitic fluid shows multiple organisms on Gram stain, very high protein (> 10 g/L), or low glucose (< 50 mg/dL).
•Calculate the score and to risk-stratify the patient; a MELD score ≥ 22 combined with a peripheral WBC count ≥ 11,000/mm³ (the 22/11 rule) predicts a 30-day mortality rate of 52%.
•Monitor renal function closely, defining AKI as a serum creatinine increase of ≥ 0.3 mg/dL within 48 hours or ≥ 50% from baseline, as renal failure is the primary driver of mortality in SBP.
•Order serum procalcitonin (PCT) as a supplementary rule-in test, as levels are typically elevated in SBP with a pooled sensitivity of 76% and specificity of 87%.

Management

•Initiate empirical antibiotic therapy immediately upon finding an ascitic ANC ≥ 250 cells/mm³; do not wait for culture results to begin treatment.
•Administer 1 g IV every 24 hours or 2 g IV every 8 hours as first-line therapy for community-acquired SBP. For patients with a history of quinolone prophylaxis or healthcare-associated infection, consider escalation to 1 g IV every 8 hours.
•Administer intravenous to prevent and reduce mortality: 1.5 g/kg body weight within 6 hours of diagnosis, followed by 1.0 g/kg on day 3. This is most critical for patients with serum creatinine > 1 mg/dL, BUN > 30 mg/dL, or total bilirubin > 4 mg/dL.
•Perform a follow-up paracentesis at 48 hours to assess treatment response; a reduction in ascitic ANC of < 25% from baseline indicates treatment failure and mandates immediate antibiotic escalation.
•Transition to oral step-down therapy with 500 mg BID or 400 mg BID once clinical improvement is noted and the patient can tolerate oral intake, typically completing a 5- to 7-day total course.
•Initiate lifelong secondary prophylaxis with 400 mg PO daily or 750 mg PO weekly following the first episode of SBP to prevent the 70% annual recurrence rate.
•Start primary prophylaxis with 400 mg PO daily in high-risk patients who have never had SBP but have ascitic protein < 15 g/L and either Child-Pugh score ≥ 9 or renal impairment (Cr ≥ 1.2 mg/dL).
•Discontinue (PPIs) unless there is a compelling indication (e.g., biopsy-proven peptic ulcer disease) to reduce the risk of recurrent translocation.
•Manage concurrent with IV 1 g/day for 7 days, which is superior to oral quinolones for preventing SBP in the setting of acute bleeding.
•Refer all patients who survive an episode of SBP for evaluation, as the 1-year survival rate is only 30-40% without transplant.
•Avoid non-selective beta-blockers (NSBBs) like in patients with SBP and refractory shock or severe AKI, though they should be resumed once the patient is stable to manage portal hypertension.

Board Review — High Yield

•Ascitic ANC ≥ 250 cells/mm³, The diagnostic threshold for SBP, regardless of culture positivity.
•Albumin (1.5g/kg day 1, 1g/kg day 3), Reduces the risk of hepatorenal syndrome and mortality by ~70%.
•Escherichia coli, The most common causative organism in community-acquired SBP.
•22/11 Rule, MELD ≥ 22 and peripheral WBC ≥ 11,000 identifies patients with > 50% 30-day mortality.
•Secondary Prophylaxis, Mandatory lifelong norfloxacin 400 mg daily after the first SBP episode.
•Ascitic Protein < 15 g/L, A key risk factor and indication for primary prophylaxis if liver/renal failure is present.
•PPI Use, Associated with a 3-fold increased risk of SBP due to bacterial overgrowth.
•48-hour Paracentesis, Necessary to confirm a > 25% drop in ANC to ensure antibiotic efficacy.

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

▸SBP is defined as an infected ascitic fluid without an evident intra-abdominal surgical source.
▸The diagnosis is anchored on an ascitic fluid absolute neutrophil count (ANC) of ≥250 cells/mm³.
▸SBP is a major precipitant of hepatorenal syndrome and acute-on-chronic liver failure, with a 25% three-month mortality rate.

HY High Yield: In patients with alcoholic hepatitis, SBP is associated with significantly higher mortality (17.3%) compared to Clostridium difficile infection (10.1%) [9].

Spontaneous bacterial peritonitis (SBP) is a severe bacterial infection of the ascitic fluid that occurs in the absence of an intra-abdominal, surgically treatable source of infection ^[1]^A1c^[14]^A1a. It represents a critical manifestation of decompensated cirrhosis and is a primary driver of morbidity and mortality in end-stage liver disease ^[1]^A1c^[15]^B2c. The condition is characterized by a profound inflammatory response within the peritoneal cavity, often precipitated by the translocation of gut-derived organisms across a compromised intestinal barrier ^[4]^D5^[16]^D5.

Synonyms and Nomenclature

SBP: Spontaneous Bacterial Peritonitis
Culture-Negative Neutrocytic (CNNA): SBP variant with elevated neutrophil count but negative bacteriological culture ^[12]^C4.
Monomicrobial Non-neutrocytic Bacterascites (MNB): Presence of bacteria in ascitic fluid without an inflammatory neutrophil response ^[12]^C4.

Clinical Classification

SBP is classified based on the context of acquisition and the inflammatory state of the ascitic fluid. Clinicians distinguish between community-acquired and hospital-acquired (nosocomial) infections to guide empirical antibiotic selection ^[6]^A1c. Furthermore, SBP is a defining component of acute decompensation (AD) in cirrhosis, which carries a higher risk of transplant-free mortality compared to non-acute decompensation ^[13]^B3b.

Variant	Ascitic Fluid Absolute Neutrophil Count (ANC)	Culture Result	Clinical Significance
Classic SBP	≥250 cells/mm³	Positive	Standard presentation; requires immediate ^[14]^A1a.
CNNA	≥250 cells/mm³	Negative	Similar clinical course to classic SBP; requires treatment ^[12]^C4.
Bacterascites	<250 cells/mm³	Positive	May represent early colonization or transient translocation ^[12]^C4.

Clinical Significance

SBP is a major cause of hospitalization, accounting for approximately 2.5% of all admissions in patients with cirrhosis ^[14]^A1a. It frequently precipitates life-threatening complications, including , , and (HRS-AKI) ^[4]^D5^[8]^D5. Mortality remains high; approximately 25% of patients die within three months of an SBP episode ^[14]^A1a. Patients with SBP and elevated ascitic soluble CD206 (>0.53 mg/L) have significantly reduced odds of 90-day survival ^[3]^B3b.

Pearl: SBP is a medical emergency where a neutrophil count ≥250 cells/mm³ in ascitic fluid mandates immediate empirical antibiotics, regardless of whether the culture eventually returns positive ^[12]^C4^[14]^A1a.

Classification of Ascitic Fluid Infection Variants

Variant	Ascitic Fluid ANC	Culture Result	Clinical Significance
Classic SBP	≥250 cells/mm³	Positive	Requires immediate empirical antibiotics ^[14]^A1a.
CNNA	≥250 cells/mm³	Negative	Clinically indistinguishable from classic SBP; requires treatment ^[12]^C4.
Bacterascites	<250 cells/mm³	Positive	May resolve spontaneously or progress to SBP ^[12]^C4.

Pathophysiology & Mechanism

▸SBP arises from a cascade of intestinal dysbiosis, where a 30-60% decline in microbial diversity and SCFA depletion weaken the mucosal barrier [16].
▸Bacterial translocation is facilitated by the cleavage of E-cadherin by specific bacterial proteases and the proteasome-mediated degradation of occludin [17].
▸Recent PPI use (within 7 days) is a major modifiable risk factor, increasing the odds of SBP by over 300% [20, 22].

HY High Yield: Patients in the lowest quartile of microbial diversity have a **threefold** increased risk of developing SBP or hepatic encephalopathy [16].

! Warning: Up to 68% of cirrhotic patients with SBP have no documented clinical indication for the PPI therapy they are receiving [20].

Bacterial translocation from the intestinal lumen to mesenteric lymph nodes serves as the primary driver for ascitic fluid infection in the setting of advanced cirrhosis ^[17]^C4^[19]^D5. This process involves a multi-step failure of the gut-liver-immune axis, where luminal dysbiosis, structural barrier disruption, and systemic immune deficits converge to allow enteric organisms to seed the peritoneal space ^[4]^D5^[16]^D5.

Luminal Dysbiosis and Microbial Shifts

Intestinal microbial ecology undergoes profound alterations in cirrhosis, characterized by a 30-60% decline in gut microbial α-diversity ^[16]^D5. These shifts are marked by:

Depletion of beneficial taxa: Over 80% of studies report a depletion of short-chain fatty acid (SCFA)-producing taxa, specifically Lachnospiraceae and Ruminococcaceae, leading to a 40-70% decrease in fecal butyrate levels ^[16]^D5.
Expansion of pathogens: Significant increases occur in Enterobacter (SMD -1.79) and Enterococcus (SMD -1.41) ^[26]^A1a. In alcohol-associated liver disease, gastric acid suppression specifically facilitates the expansion of cytolytic Enterococcus faecalis, which promotes hepatocyte death ^[27]^D5.
Metabolic derangements: Secondary bile acids are reduced by approximately 50%, suppressing FXR/TGR5 signaling and weakening epithelial defense ^[16]^D5.

Intestinal Barrier Failure

Structural integrity of the colonic epithelium is compromised by both host and bacterial factors. Patients with cirrhosis exhibit reduced colonic mucus thickness, which facilitates direct bacteria-to-epithelial cell contact ^[17]^C4.

Junctional Protein Degradation: SBP-inducing bacteria, such as Escherichia coli and Proteus mirabilis, exploit the host proteasome to induce ubiquitination and degradation of occludin ^[17]^C4.
Protease-Mediated Cleavage: A novel bacterial protease activity has been identified that directly cleaves E-cadherin structures, further disrupting cell-to-cell junctions ^[17]^C4.
Permeability Thresholds: Altered intestinal permeability is found in 45% of cirrhotic patients compared to 4% of controls ^[18]^B3b. This impairment is most severe in C patients (75%) and those with a history of ascitic infection (100%) ^[18]^B3b.

Cirrhosis-Associated Immune Dysfunction (CAID)

Once bacteria translocate, the systemic and local immune environments fail to contain the challenge. CAID is characterized by a paradoxical state where systemic immune cells are primed and inflammatory, yet fail to mount robust responses to pathogens ^[4]^D5. Endotoxin concentrations are increased two- to fourfold, exacerbating systemic inflammation and ^[16]^D5. In the ascitic fluid, low complement levels and impaired phagocytic activity allow for the survival and proliferation of translocated organisms ^[19]^D5.

Role of Gastric Acid Suppression

Pharmacologic acid suppression, particularly with (PPI) therapy, is a significant modifier of SBP risk. PPI use is associated with a threefold increase in SBP risk (OR 3.15, 95%; NNH not calculable from reported data) ^[22]^A1a. Recent PPI use within the past 7 days carries the highest risk; patients who have not taken PPIs in the previous 90 days are nearly 70% less likely to develop SBP than those with recent exposure ^[20]^B3b.

Mechanism Flowchart

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Antibiotic Prophylaxis	Standard of care for high-risk patients to prevent SBP ^[1]^A1c^[24]^D5	Potential harm due to antimicrobial resistance and lack of clear mortality benefit ^[30]^D5	Weak evidence ^[30]^D5	Urgent need for ^[30]^D5

Pearl: Avoid unnecessary acid suppression in cirrhotic patients with , as recent PPI use increases the risk of ascitic infection three-fold ^[20]^B3b^[22]^A1a.

Microbial Alterations in Cirrhosis

Taxon	Change in Cirrhosis	Pathogenic Impact
Lachnospiraceae	Depleted	Reduced SCFA production and weakened epithelial defense ^[16]^D5
Enterococcus	Increased	Enhanced translocation and exotoxin-induced hepatocyte death ^[26]^A1a^[27]^D5
Lactobacillus	Decreased	Loss of protective commensal signaling ^[26]^A1a
Enterobacter	Increased	Common source of Gram-negative ascitic seeding ^[26]^A1a

Epidemiology, Etiology & Risk Factors

▸SBP occurs in approximately 16.7% of patients with newly decompensated cirrhosis and is associated with a 3-fold higher risk of infection compared to non-cirrhotic liver disease.
▸Low ascitic protein (<15 g/L) and high serum bilirubin (≥3 mg/dL) are the primary clinical indicators for high-risk status.
▸Iatrogenic factors, particularly the use of proton pump inhibitors and recent endoscopic procedures, significantly increase the risk of both initial and enterococcal-specific SBP episodes.

HY High Yield: In patients with cirrhosis and ascites, PPIs are often prescribed without a clear indication (up to 47% of cases). Given the OR of 4.31 for SBP, deprescribing unnecessary PPIs is a high-priority modifiable risk reduction strategy.

Bacterial translocation from the gut into the peritoneal cavity serves as the primary driver for infection in patients with advanced cirrhosis ^[49]^D5. While enteric Gram-negative bacteria like Escherichia coli are the most frequent isolates, the epidemiological landscape is shifting toward Gram-positive and multidrug-resistant organisms in specific clinical contexts ^[33]^A1b^[44]^C4.

Incidence and Prevalence

The risk of developing serious infections, including spontaneous bacterial peritonitis (SBP), scales directly with the severity of underlying liver disease. In a large cohort of over 1.6 million patients with chronic liver disease, the development of serious infection was significantly higher in compensated cirrhosis (aHR 1.99) and decompensated cirrhosis (aHR 3.31) compared to those without cirrhosis ^[43]^B2c. Among veterans with newly decompensated cirrhosis, approximately 16.7% develop at least one episode of SBP during follow-up ^[66]^B3b.

Modifiable and Clinical Risk Factors

Advanced liver failure and impaired renal function are the strongest predictors of SBP. Specific laboratory thresholds associated with high risk include ascitic fluid protein <15 g/L, serum bilirubin ≥3 mg/dL, and serum creatinine ≥1.2 mg/dL ^[32]^A1b.

Proton Pump Inhibitor (PPI) Use: Outpatient therapy is independently associated with SBP (OR 4.31), likely due to gastric acid suppression allowing for bacterial colonization and translocation ^[53]^B3b. One cohort study found an annual SBP incidence of 10.6% in PPI users versus 5.8% in non-users ^[46]^B2b.
Hemorrhage: Acute variceal bleeding significantly increases infection risk; prophylactic reduce the incidence of SBP from 12% to 2% compared to no prophylaxis in this setting ^[33]^A1b.
Invasive Procedures: Recent gastrointestinal endoscopy is a risk factor for enterococcal SBP (OR 3.17) ^[44]^C4.
Medication Interactions: Use of 20 mg daily has been shown to reduce the incidence of SBP (sHR 0.30) in patients following a variceal bleed ^[36]^A1b. Conversely, while is used for prophylaxis, its use is associated with a higher prevalence of quinolone-resistant bacteria ^[33]^A1b.

Risk Factor Summary Table

Factor	Association (OR/HR/RR)	Evidence Level
PPI Use	OR 4.31 ^[53]^B3b	3b
Ascitic Protein <15 g/L	sHR 0.35 (for death) ^[31]^A1b	1b
Decompensated Cirrhosis	aHR 3.31 (for infection) ^[43]^B2c	2c
Simvastatin Use	sHR 0.30 ^[36]^A1b	1b
Previous Antibiotic Use	OR 5.63 (for Enterococcus) ^[44]^C4	4

Pearl: Ascitic fluid protein levels below 15 g/L represent a critical threshold where the loss of local opsonic activity necessitates consideration for primary antibiotic prophylaxis ^[31]^A1b^[32]^A1b.

Risk Factors for Spontaneous Bacterial Peritonitis

Risk Factor	Clinical Context	Impact
Low Ascitic Protein	<15 g/L	Increases susceptibility to bacterial seeding
PPI Therapy	Chronic use	OR 4.31 for SBP development
GI Bleeding	Acute variceal bleed	High-risk window for translocation
Liver Severity	Child-Pugh C	Highest incidence of spontaneous infection
Renal Dysfunction	Creatinine ≥1.2 mg/dL	Predicts both occurrence and poor prognosis

Clinical Presentation

▸Clinical symptoms are often subtle; abdominal pain and fever may be absent in a significant portion of patients.
▸Acute kidney injury (serum creatinine increase ≥0.3 mg/dL) at the time of diagnosis is a major independent predictor of both inpatient and long-term mortality [72, 75].
▸Worsening hepatic encephalopathy is a common presenting feature of SBP, even in the absence of abdominal symptoms [76, 77].

HY High Yield: The absence of classic peritoneal signs (rigidity, rebound) does not rule out SBP, as ascitic fluid prevents the parietal and visceral peritoneum from contacting each other [78].

! Warning: Hepatorenal syndrome (HRS-AKI) occurs in approximately 35-58% of SBP cases and carries a poor prognosis without rapid volume expansion with albumin [8, 75].

Building upon the epidemiological risk factors of advanced cirrhosis, the clinical presentation of this infection is often subtle, as the systemic inflammatory response is frequently blunted in the setting of end-stage liver disease ^[74]^A1a^[76]^B3b. While some patients present with overt signs of sepsis, many exhibit only minor clinical shifts or isolated organ dysfunction, particularly acute kidney injury (AKI) ^[72]^D5^[75]^B3b.

Presenting Symptoms

The onset of symptoms is typically subacute, progressing over several days. Abdominal pain is the most frequent complaint, though its absence does not exclude the diagnosis, especially in patients with chronic who may have high baseline abdominal distension ^[78]^C4^[79]^C4.

Abdominal Pain: Present in approximately 50-80% of cases; typically diffuse and continuous ^[78]^C4^[79]^C4.
Fever and Chills: Often low-grade; high-grade fever may suggest a more virulent organism or secondary peritonitis ^[74]^A1a^[79]^C4.
Altered Mental Status: New-onset or worsening (HE) is a hallmark presenting feature in patients with HBV-related or alcohol-related cirrhosis ^[76]^B3b^[77]^B3b.
Distress: Nausea, vomiting, or diarrhea may precede the diagnosis ^[76]^B3b.

Physical Examination Findings

Physical findings are often non-specific and may be masked by the underlying features of and cirrhosis.

Abdominal Tenderness: Diffuse tenderness is common, but classic "board-like" rigidity and rebound tenderness are frequently absent due to the insulating effect of the ascitic fluid ^[78]^C4.
Ascites: Clinical evidence of fluid (shifting dullness, fluid wave) is nearly universal ^[72]^D5^[79]^C4.
Systemic Signs: Tachycardia and hypotension may indicate progressing systemic inflammatory response syndrome (SIRS) or early septic shock ^[74]^A1a.
Neurological Signs: Asterixis or slowed mentation indicating HE ^[76]^B3b^[77]^B3b.

Phenotypic Variants

The presentation can be categorized by the dominant clinical manifestation, which often dictates the urgency of the diagnostic .

Variant	Key Features	Frequency
Symptomatic SBP	Fever, abdominal pain, and localized tenderness.	Common
Silent SBP	Asymptomatic; discovered on routine paracentesis or during workup for unrelated decompensation.	Moderate
Encephalopathic	Worsening HE without localizing abdominal signs.	Common ^[76]^B3b
Renal-Dominant	Unexplained AKI or worsening renal function as the primary sign.	High in advanced disease ^[72]^D5^[75]^B3b

Red Flags

Certain findings necessitate immediate intervention and high-level care, as they correlate with significantly increased inpatient mortality ^[59]^B3b^[75]^B3b.

Acute Kidney Injury (AKI): Defined as a serum creatinine increase of ≥0.3 mg/dL within 48 hours or ≥50% from baseline ^[72]^D5. Serum creatinine at diagnosis is an independent predictor of 32-month mortality (HR 1.002, P = 0.023) ^[75]^B3b.
(HRS-AKI): Functional renal failure persisting despite volume repletion ^[72]^D5^[8]^D5.
High CLIF- Score: A score ≥7 indicates a critically ill phenotype where empirical carbapenem may be superior to third-generation cephalosporins ^[59]^B3b.
Hypotension: SBP is a common trigger for vasodilatory shock in cirrhosis ^[8]^D5.

Atypical Presentations

Clinicians must maintain a high index of suspicion for extra-peritoneal sources that mimic or coexist with SBP. For example, septic arthritis of the lumbar facet joint can present with abdominal and lumbar pain, mimicking the peritonitis of cirrhosis ^[79]^C4. Additionally, in patients on hemodialysis, opportunistic pathogens like Staphylococcus cohnii may cause persistent abdominal pain that fails to respond to standard empirical therapy, requiring metagenomic next-generation sequencing (mNGS) for identification ^[78]^C4.

Following the clinical assessment, the next critical step is the definitive ascitic fluid analysis, which is detailed in the Diagnosis & Workup section.

Pearl: In a patient with cirrhosis, any unexplained clinical deterioration, including worsening encephalopathy or a creatinine rise of ≥0.3 mg/dL, is SBP until proven otherwise by paracentesis ^[72]^D5^[75]^B3b.

Clinical Predictors of Mortality in SBP

Parameter	Impact on Mortality	Significance (P-value)
Serum Creatinine	HR 1.002 (32-month); HR 1.003 (Inpatient)	P = 0.023; P = 0.035 ^[75]^B3b
Ascitic Fluid Neutrophils	Independent predictor of inpatient mortality	P = 0.005 ^[75]^B3b
Positive Fluid Culture	HR 1.679 (32-month mortality)	P = 0.008 ^[75]^B3b
CLIF-SOFA Score ≥7	Associated with higher mortality unless treated with carbapenems	P = 0.002 ^[59]^B3b

Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)

▸The diagnosis of SBP is established by an ascitic fluid PMN count ≥ 250 cells/mm³, regardless of culture positivity.
▸Renal dysfunction (elevated creatinine or BUN) is the strongest predictor of mortality in patients with SBP, increasing the risk from 11% to 67%.
▸Leukocyte esterase reagent strips have high negative predictive value (99.1%) in outpatients but lack the sensitivity (as low as 45%) required for definitive diagnosis in hospitalized patients.

Dx Diagnostic Essentials: Diagnostic paracentesis with ascitic fluid PMN count and bedside inoculation into blood culture bottles is the mandatory first step for any cirrhotic patient with clinical deterioration.

HY High Yield: Proton pump inhibitors (PPIs) are associated with a significantly increased risk of developing SBP (HR 1.751, 95%) and should be discontinued if a clear indication is lacking.

Diagnosis relies on the rapid identification of infected ascitic fluid in patients with cirrhosis, as clinical symptoms are often subtle or absent ^[1]^A1c. Because delayed treatment significantly increases mortality, diagnostic is mandatory for all patients with cirrhosis and new-onset or those hospitalized for any cirrhosis-related complication ^[1]^A1c^[80]^B2a.

Gold-Standard Test: Ascitic Fluid Analysis

The gold standard for diagnosing spontaneous bacterial peritonitis (SBP) is an ascitic fluid polymorphonuclear (PMN) cell count ≥ 250 cells/mm³ ^[1]^A1c^[82]^B2b. This threshold is used regardless of the culture results, as ascitic fluid cultures are frequently negative due to low bacterial density ^[82]^B2b.

PMN Count: Calculated by multiplying the total white blood cell (WBC) count by the percentage of neutrophils. A count ≥ 250 cells/mm³ warrants immediate empiric antibiotic therapy ^[1]^A1c.
Ascitic Fluid Culture: To maximize yield, 10 mL of fluid should be inoculated into aerobic and anaerobic blood culture bottles at the bedside ^[82]^B2b.
Biochemical Markers: Ascitic fluid lactoferrin (AFLAC) at a cutoff of 242 ng/mL demonstrates a sensitivity of 95.5% and specificity of 97% (AUC 0.98) ^[82]^B2b. Ascitic calprotectin > 21 μg/mL also shows high accuracy, with a sensitivity of 85.7% and specificity of 89.5% ^[89]^B2b.

Laboratory Studies and Biomarkers

Standard laboratory tests are used to assess severity and predict outcomes rather than to establish the primary diagnosis. Renal dysfunction is the most critical independent predictor of mortality; patients with renal impairment face a 67% mortality rate compared to 11% in those with normal function ^[80]^B2a.

Serum Procalcitonin (PCT): A meta-analysis found PCT has a pooled sensitivity of 0.76 and specificity of 0.87 for SBP, making it a useful rule-in test (DOR 29.50) ^[74]^A1a^[90]^B2a.
Neutrophil-to-Lymphocyte Ratio (NLR): Elevated NLR levels are associated with SBP (pooled sensitivity 92.07%, specificity 72.58%) ^[92]^B2a.
Severity Labs: Serum urea ≥ 11 mmol/L and bilirubin ≥ 68 μmol/L identify high-risk patients who require aggressive , including infusion ^[67]^B3b.

Imaging and Endoscopy

Imaging is primarily used to confirm the presence of ascites and exclude secondary causes of peritonitis (e.g., perforated viscus).

Cross-sectional Imaging: CT or MRI can identify complications such as (PVT) or (HCC) ^[1]^A1c^[83]^B2b. Loss of paraspinal muscle mass (low PSMI) on CT is a gender-independent predictor of SBP development (HR 0.901) ^[87]^B3b.
Endoscopy: While not diagnostic for SBP, endoscopy is used for secondary prophylaxis of variceal bleeding. The combination of or with endoscopic variceal ligation (EVL) is standard for managing complications ^[65]^D5.

Diagnostic Algorithm

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Reagent Strips	Highly efficient for excluding SBP in outpatients (NPV 99.1%) ^[84]^B2b.	Not recommended due to low sensitivity (45.3%) in large studies ^[86]^B2a.	Moderate	Strips may only be useful for rapid exclusion in low-prevalence settings.
Metagenomic Sequencing (mNGS)	High accuracy (AUC 0.95) for pathogen identification ^[95]^B2a.	Not yet standard of care; limited by cost and availability.	Emerging	May optimize therapy in culture-negative cases.

Pearl: Never wait for culture results to treat; an ascitic PMN count ≥ 250 cells/mm³ is the only trigger needed to initiate in a cirrhotic patient ^[1]^A1c^[82]^B2b.

Diagnostic Performance of SBP Biomarkers

Biomarker	Cutoff	Sensitivity	Specificity	AUC
Ascitic PMN Count	250 cells/mm³	Gold Standard	-	-
Ascitic Lactoferrin	242 ng/mL	95.5%	97%	0.98
Ascitic Calprotectin	21 μg/mL	85.7%	89.5%	0.947
Serum Procalcitonin	-	76%	87%	0.90
mNGS (Ascites)	-	94%	81%	0.95

Severity, Staging & Risk Stratification (GI Scores)

▸MELD score ≥22 and peripheral leukocyte count ≥11 × 10⁹ cells/L are the strongest validated predictors of 30-day mortality in SBP.
▸Irreversible acute kidney injury (AKI) increases 30-day mortality 10-fold compared to patients without renal dysfunction.
▸Each hour of delay in performing diagnostic paracentesis increases in-hospital mortality by 3.3%.

HY High Yield: In patients with SBP-associated septic shock, the mortality rate exceeds 80%. Survival is highly dependent on the speed of 'appropriate' antimicrobial therapy, which must be initiated within the first few hours of presentation [45].

Prognostication in spontaneous bacterial peritonitis (SBP) relies on the integration of hepatic reserve, renal function, and the systemic inflammatory response. While diagnostic confirms the presence of infection, the clinical trajectory is dictated by the degree of underlying decompensation, with median survival dropping to 9 months in further decompensated stages ^[97]^D5. Risk stratification is essential to identify patients requiring intensive care or early liver transplant evaluation, as SBP-associated septic shock carries a hospital mortality rate of 81.8% ^[45]^B3b.

Validated Prognostic Scoring Systems

The Model for End-Stage Liver Disease ( ) and scores are the primary tools for assessing baseline risk. For every one-point increase in the MELD score, the risk of developing SBP increases by 11% (OR 1.11) ^[101]^B3b.

MELD Score: A MELD score ≥22 is a validated independent predictor of 30-day mortality ^[104]^B3b. Patients with MELD ≥25 have a 9.67-fold increased odds of developing SBP compared to those with MELD ≤15 ^[101]^B3b. On-treatment improvement in MELD score correlates with reduced mortality and fewer subsequent hepatic events ^[100]^B3b.
The 22/11 Rule: This specific SBP risk model combines MELD ≥22 and a peripheral blood leukocyte count ≥11 × 10⁹ cells/L. Patients with both factors have a 30-day mortality rate of 52%, whereas those with neither have a mortality rate of ≤10% ^[104]^B3b.
Poca Model: A predictive model for high-risk SBP (bilirubin ≥68 μmol/L or urea ≥11 mmol/L) utilizes serum urea, blood leukocyte count, , and mean arterial pressure (MAP). A model value ≥0.245 identifies patients with a 57.1% in-hospital mortality rate ^[67]^B3b.
and : In the setting of acute-on-chronic liver failure (ACLF), higher SOFA scores are independently associated with poor prognosis ^[35]^A1b. In SBP-associated septic shock, each unit increase in APACHE II score increases the odds of mortality by 1.45 ^[45]^B3b.

Renal Function and Mortality Risk

Renal impairment is the most critical determinant of survival during an acute SBP episode. Acute kidney injury (AKI), defined by a >50% increase in serum creatinine from baseline or an increase of ≥0.3 mg/dL within 48 hours, occurs in approximately 49% of hospitalized cirrhotic patients with infection ^[2]^B2b.

Renal Status	30-Day Mortality Rate	Clinical Significance
Irreversible AKI	80%	10-fold higher mortality than no AKI ^[2]^B2b
Partial Recovery	40%	Intermediate risk requiring close monitoring ^[2]^B2b
Complete Recovery	15%	Improved prognosis with early intervention ^[2]^B2b
No AKI	7%	Baseline mortality for infected cirrhotics ^[2]^B2b

Biomarkers and Novel Stratification Tools

Beyond standard scores, specific biomarkers indicate the severity of bacterial translocation and systemic inflammation.

Ascitic Soluble CD206: Levels >0.53 mg/L in ascitic fluid are associated with reduced 90-day survival, reflecting the activation of inflammatory peritoneal macrophages ^[3]^B3b.
von Willebrand Factor (vWF): Plasma vWF levels independently predict the requirement for paracentesis and the risk of bacterial infections, including SBP (HR 1.09), regardless of the severity of ^[106]^B2b.
Serum Lactate: In patients with SBP-associated septic shock, each unit increment in serum lactate increases the odds of mortality by 2.34 ^[45]^B3b.

Impact of Procedural Timing

Timing of diagnostic paracentesis is a modifiable risk factor that gates clinical outcomes. Delayed paracentesis (>12 hours from admission) is associated with a 2.7-fold increased risk of in-hospital mortality ^[102]^B2b. Each hour of delay in performing paracentesis correlates with a 3.3% increase in mortality after adjusting for MELD and creatinine levels ^[102]^B2b. Furthermore, each hour of delay in administering appropriate antimicrobial therapy in septic shock increases hospital mortality by 1.86 times ^[45]^B3b.

Pearl: The "22/11" rule (MELD ≥22 and WBC ≥11,000) provides a rapid bedside assessment; patients meeting both criteria face a >50% 30-day mortality risk and should be prioritized for aggressive and transplant consultation ^[104]^B3b.

Predictors of In-Hospital Mortality in SBP

Variable	Threshold	Effect Size (Mortality/Risk)	Source
MELD Score	≥22	OR 4.6 for 30-day mortality	^[104]^B3b
WBC Count	≥11 × 10⁹/L	OR 2.5 for 30-day mortality	^[104]^B3b
Serum Lactate	Per unit increase	OR 2.34 in septic shock	^[45]^B3b
Paracentesis Timing	>12 hours	2.7-fold increase in mortality	^[102]^B2b
Antibiotic Delay	Per hour	1.86-fold increase in mortality (shock)	^[45]^B3b

Acute Management

▸Empirical antibiotics (ceftriaxone, cefotaxime, or ciprofloxacin) should be started immediately when ascitic PMN count exceeds 250/mm³.
▸Intravenous albumin is essential for preventing acute kidney injury and hepatorenal syndrome in patients with SBP.
▸A 48-hour follow-up paracentesis is the gold standard for assessing treatment response; failure to reduce PMN count by 25% requires therapy escalation.

Rx Drug of Choice: [[Ceftriaxone]] 1 g IV daily is the preferred first-line agent for SBP and for prophylaxis in cirrhotic patients with gastrointestinal hemorrhage [33, 98].

! Warning: Quinolone resistance is increasing; avoid [[ciprofloxacin]] or [[norfloxacin]] for acute treatment if the patient was already receiving them for prophylaxis [33, 116].

Following the identification of high-risk features and severity scoring, immediate therapeutic intervention is required to prevent rapid clinical deterioration. The of spontaneous bacterial peritonitis (SBP) centers on rapid antibiotic administration and volume expansion with intravenous to mitigate the risk of (HRS) and acute-on-chronic liver failure (ACLF) ^[97]^D5^[116]^A1b.

Step 1: Immediate Empirical Antibiotic Initiation

Empirical therapy must be initiated as soon as the ascitic fluid polymorphonuclear (PMN) cell count is confirmed to be >250/mm³ ^[98]^A1b. The choice of agent depends on the clinical setting (community-acquired vs. healthcare-associated) and prior exposure to quinolone prophylaxis ^[116]^A1b.

First-line agents: , , and demonstrate comparable efficacy in community-acquired SBP ^[98]^A1b. In a multicenter trial, resolution rates at 120 hours were 67.8% for , 77.0% for , and 73.6% for (P = 0.388) ^[98]^A1b.
Switch therapy: In patients not previously on quinolone prophylaxis, an intravenous-to-oral step-down schedule using is cost-effective and achieves resolution in approximately 80% of cases, similar to intravenous (84%) ^[116]^A1b.

Step 2: Intravenous Albumin for Renal Protection

Intravenous is utilized to increase effective arterial blood volume and prevent AKI ^[97]^D5. While its use is standard in SBP, its benefit in non-SBP infections is less clear, though it may assist in ACLF resolution ^[40]^A1b.

Indication: The AGA 2023 update emphasizes use in SBP to prevent AKI and death ^[97]^D5.
Dosing in HRS-AKI: If SBP is complicated by type 1 hepatorenal syndrome, the combination of (2-12 mg/day) and (20-40 g/day) is used for reversal ^[116]^A1b.

Step 3: Response Assessment and Monitoring

A follow-up at 48 hours is critical to guide therapy ^[98]^A1b. A reduction in the ascitic absolute neutrophil count (ANC) by >25% after 48 hours indicates an early response ^[117]^A1b. Failure to achieve this threshold necessitates a change in the antibiotic regimen ^[98]^A1b.

Step 4: Management of Concurrent Complications

Acute management often occurs alongside other decompensating events, most notably hemorrhage.

Variceal Bleeding: In patients with advanced cirrhosis and hemorrhage, intravenous 1 g/day is superior to oral 400 mg BID for preventing SBP and bacteremia (2% vs. 12%, P = 0.03) ^[33]^A1b.
Vasoactive Support: is the vasoactive drug of choice when variceal hemorrhage is suspected or confirmed ^[97]^D5.

Drug / Modality Comparison Table

Option	Indication	Dose / Specifics	Key Trial	Outcome	Evidence Level
Ceftriaxone	First-line SBP	1 g IV daily	Yim et al. ^[98]^A1b	77% resolution at 120h	1b
	Switch therapy	IV then PO	Angeli et al. ^[116]^A1b	80% resolution; cost-saving	1b
+ GM-CSF	Difficult-to-treat SBP	1 g TID + 1.5 mcg/kg	Prakash et al. ^[117]^A1b	60% early response vs 31.8%	1b
+	SBP with Type 1 HRS	2-12 mg/d + 20-40 g/d	Angeli et al. ^[116]^A1b	63% HRS reversal	1b

Dosing Table

Drug	Starting dose	Target / max dose	Renal adjustment	Hepatic adjustment	Key monitoring
Ceftriaxone	1 g IV daily	2 g IV daily	No adjustment	No adjustment	Biliary sludge
	400 mg IV q12h	500-750 mg PO BID	eGFR <30: 50% dose	No adjustment	QTc interval
	1 g IV q8h	2 g IV q8h	Required for CrCl <50	No adjustment	Seizure risk
	0.5-1 mg IV q6h	12 mg/day	No adjustment	No adjustment	Ischemia, Na+

Treatment Failure Protocol

Treatment failure is defined by a <25% decrease in ascitic PMN count at 48 hours or clinical worsening ^[117]^A1b.

Culture Review: Check for multi-drug resistant organisms (MDROs) or quinolone-resistant strains ^[33]^A1b.
Antibiotic Escalation: Transition to carbapenems (e.g., ) if not already utilized ^[117]^A1b.
Adjunctive Therapy: Consider adding GM-CSF to enhance host immune response and antibiotic efficacy ^[117]^A1b.
Liver Support: Extracorporeal support (e.g., FPSA) has been studied in ACLF but does not significantly increase 28-day or 90-day survival (66% vs 63% at day 28) ^[35]^A1b.

What NOT to Do

Do NOT delay while awaiting culture results; initiate therapy based on PMN count >250/mm³ ^[98]^A1b.
Do NOT use oral for prophylaxis in A patients with GI bleed; it may be withheld without increasing 5-day infection risk (7.0% vs 11.6%) ^[61]^A1b.
Do NOT rely on for primary SBP prophylaxis; it does not improve 12-month survival (P = 0.74) ^[60]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Choice of first-line antibiotic	AASLD 2021 Guidance, supports , , or ^[98]^A1b	Traditional Practice, often prioritizes third-generation cephalosporins over quinolones	Mild	Quinolones remain effective for community-acquired SBP if no prior exposure ^[98]^A1b^[116]^A1b.
Prophylaxis in Child-Pugh A	Standard Care, prophylactic antibiotics for all GI bleeds	Gupta et al. 2025, antibiotics can be withheld in stable Child-Pugh A ^[61]^A1b	Moderate	Potential to reduce antibiotic resistance in low-risk populations.

Pearl: Initiate antibiotics immediately upon finding ascitic PMN >250/mm³ and perform a follow-up paracentesis at 48 hours; a PMN reduction of <25% mandates immediate antibiotic escalation ^[98]^A1b^[117]^A1b.

Antibiotic Efficacy in SBP Resolution

Antibiotic	Resolution Rate (120h)	1-Month Mortality	Setting
	67.8%	Similar across groups	Community-acquired
Ceftriaxone	77.0%	Similar across groups	Community-acquired
	73.6%	Similar across groups	Community-acquired

Long-term & Definitive Medical Management

▸Primary prophylaxis with norfloxacin 400 mg daily is indicated for ascitic protein <15 g/L with either Child-Pugh ≥9 or renal impairment, reducing 1-year SBP risk from 61% to 7%.
▸Weekly ciprofloxacin 750 mg is a non-inferior, more convenient alternative to daily norfloxacin for secondary prophylaxis.
▸Non-antibiotic therapies, specifically carvedilol and simvastatin, significantly reduce the incidence of infection and improve long-term survival by modulating portal pressure and inflammation.

Rx Drug of Choice: Norfloxacin 400 mg PO daily is the established first-line agent for both primary and secondary prophylaxis, though local resistance patterns should guide use.

! Warning: Recent large-scale cohort data (N > 11,000) suggest secondary prophylaxis may paradoxically increase recurrence risk in environments with high fluoroquinolone resistance (OR 4.32 for resistance) [5].

Transitioning from acute stabilization to long-term requires a dual focus on preventing recurrence and addressing the underlying drivers of . While has historically served as the cornerstone of maintenance therapy, emerging evidence regarding antibiotic resistance and the survival benefits of non-antibiotic agents like and is reshaping the definitive care pathway ^[31]^A1b^[36]^A1b^[37]^A1b.

Step 1: Risk Stratification for Primary Prophylaxis

Primary prophylaxis is indicated for patients who have never experienced an episode but meet high-risk criteria based on ascitic fluid analysis and liver function ^[32]^A1b^[118]^A1a.

Indications for Primary Prophylaxis:
Ascitic fluid protein <15 g/L AND at least one of the following:
≥9 with serum bilirubin ≥3 mg/dL ^[32]^A1b.
Impaired renal function: serum creatinine ≥1.2 mg/dL, BUN ≥25 mg/dL, or serum sodium ≤130 mEq/L ^[32]^A1b.
First-line Agent: Norfloxacin 400 mg PO daily ^[31]^A1b^[32]^A1b.
Evidence: In patients with low protein , norfloxacin reduced the 1-year probability of developing a first episode from 61% to 7% (P <.001) and improved 1-year survival from 48% to 60% (P =.05) ^[32]^A1b. A meta-analysis confirmed that fluoroquinolone prophylaxis reduces mortality (OR 0.60, 95% CI 0.37-0.97) ^[118]^A1a.

Step 2: Secondary Prophylaxis and Recurrence Prevention

Secondary prophylaxis is traditionally initiated immediately following the completion of acute treatment to prevent the high rate of recurrence ^[41]^A1a^[127]^A1a.

Standard Regimen: Norfloxacin 400 mg PO daily ^[39]^A1b.
Alternative Regimen: Ciprofloxacin 750 mg PO once weekly is non-inferior to daily norfloxacin, with 1-year transplant-free survival rates of 73.7% vs 72.7% (P =.970) ^[39]^A1b.

Step 3: Optimization of Portal Hemodynamics and Adjunctive Therapy

Reducing the (HVPG) directly correlates with a decreased risk of bacterial translocation and subsequent infection ^[114]^B2b.

: The addition of simvastatin 20 mg daily to standard care reduces the incidence of infection (sHR 0.30, 95% CI 0.11-0.81) and improves long-term survival (HR 0.48, 95% CI 0.29-0.81) ^[36]^A1b.
Vasoactive Agents: In patients with severe ascites, adding to reduces the incidence of infection from 15.7% to 10% (P = 0.03) by facilitating higher doses of NSBBs ^[62]^A1b.

Step 4: Management of Treatment Non-Response

For "difficult-to-treat" cases where standard fail to clear the ascitic fluid, immune modulation may be required ^[117]^A1b.

Alternative Antibiotics: 400 mg PO twice daily may reduce overall complications in advanced cirrhosis ( ≥9), though it did not improve 12-month survival in all-comer primary prophylaxis trials ^[60]^A1b^[124]^A1b.

Step 5: Definitive Disposition

Because the 1-year mortality following a single episode exceeds 60%, all patients should be evaluated for definitive therapy ^[119]^B2a.

: This remains the only curative intervention. SBP is considered a sentinel event indicating the need for immediate transplant listing ^[119]^B2a.
Quality Improvement: Implementation of electronic checklists for discharge, including prompts for secondary prophylaxis and for encephalopathy, reduces 30-day readmission odds by 40% ^[123]^B2b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength of Disagreement	Implication for Practice
Utility of Secondary Prophylaxis	AASLD/Traditional Standard, Mandatory lifelong prophylaxis after the first episode to prevent recurrence ^[120]^D5.	Emerging VA/TriNetX Data, Secondary prophylaxis may increase recurrence risk (HR 1.68) due to multi-drug resistant organisms ^[5]^B3b^[66]^B3b.	Strong	Clinicians must weigh the benefit of prevention against the risk of selecting for highly resistant flora in their specific hospital environment.
Rifaximin for Primary Prophylaxis	Zeng et al. (2021), Low-dose rifaximin (400 mg BID) prevents complications and improves survival in Child-Pugh ≥9 ^[124]^A1b.	Thévenot et al. (2025), Rifaximin did not improve 12-month survival or complication rates in severe cirrhosis with low protein ascites ^[60]^A1b.	Moderate	Rifaximin is not currently a standard substitute for norfloxacin in primary prophylaxis but may benefit highly adherent patients.

Dosing Table for Long-term Management

Starting Dose	Target / Max Dose	Renal Adjustment	Hepatic Adjustment	Key Monitoring
400 mg PO daily	400 mg PO daily	CrCl <30: 400 mg every 48h	No adjustment	Resistance patterns
750 mg PO weekly	750 mg PO weekly	eGFR <30: Use with caution	No adjustment	QTc interval
6.25 mg PO daily	12.5 mg PO daily	No adjustment	Avoid in Child-Pugh C	HR, SBP
20 mg PO daily	20 mg PO daily	eGFR <30: 5 mg daily	Avoid in active liver disease	CPK, LFTs
400 mg PO BID	550 mg PO BID	No adjustment	No adjustment	C. difficile signs

Pearl: While norfloxacin remains the standard for primary prophylaxis in low-protein ascites, the 1-year mortality after any SBP episode remains near 66%; therefore, the most critical "long-term management" step is immediate referral for liver transplantation evaluation ^[32]^A1b^[119]^B2a.

Prophylaxis Efficacy Summary

Strategy	Population	Outcome	Effect Size (95% CI)	Evidence Level
Norfloxacin (Primary)	Low protein ascites	1-year SBP incidence	7% vs 61% (P < .001)	1b ^[32]^A1b
Norfloxacin (Primary)	Advanced cirrhosis	6-month mortality	HR 0.59 (0.35-0.99)	1b ^[31]^A1b
Simvastatin (Adjunct)	Post-variceal bleed	Mortality	HR 0.48 (0.29-0.81)	1b ^[36]^A1b
Carvedilol (Primary)	New-onset ascites	Complicated ascites	38.5% vs 67.3% (P = .03)	1b ^[37]^A1b

Endoscopic & Procedural Management

▸Diagnostic paracentesis with an ascitic neutrophil count >250/mm³ remains the gold standard for SBP diagnosis and should be performed on all cirrhotic admissions with ascites [128].
▸Combining carvedilol with endoscopic variceal ligation (EVL) significantly reduces first variceal bleeds and mortality in Child-Pugh B and C patients compared to monotherapy [38].
▸Early TIPS placement (within 72 hours) in high-risk patients with acute variceal bleeding improves 1-year transplantation-free survival from 73% to 86% [130].

! Warning: Retrospective data suggest that prolonged use of proton pump inhibitors (PPIs) in patients with cirrhosis may increase the incidence of spontaneous bacterial peritonitis [135].

HY High Yield: In patients with CTP B/C cirrhosis, the combination of carvedilol and EVL reduced 1-year mortality to 6.3%, compared to 20% with carvedilol alone and 14.5% with EVL alone [38].

Long-term medical of often requires integration with procedural interventions to mitigate the risk of bacterial translocation and subsequent infection. While pharmacological therapy remains the cornerstone of prophylaxis, endoscopic and minimally invasive vascular procedures provide critical mechanical and hemodynamic stabilization in patients with advanced cirrhosis.

Step 1: Diagnostic and Therapeutic

Diagnostic paracentesis is the mandatory first step for any patient with new-onset or clinical deterioration to rule out SBP ^[128]^A1c.

Indications: Perform immediately upon hospital admission for all cirrhotic patients with ascites, or in those with GI bleeding, shock, fever, , or worsening renal function ^[128]^A1c.
Diagnostic Threshold: An ascitic neutrophil count >250/mm³ is the gold standard for diagnosis ^[128]^A1c.
Repeat Paracentesis: Consider a second procedure at 48 hours if there is an inadequate clinical response to or if secondary peritonitis is suspected ^[128]^A1c.

Step 2: Endoscopic Variceal Management

Endoscopic interventions primarily target the prevention of variceal hemorrhage, which is a major precipitant of SBP. The British Society of Gastroenterology (BSG) 2020 guidelines recommend prophylactic antibiotics for all patients with GI bleeding and underlying ascites to prevent SBP development ^[128]^A1c.

Primary Prophylaxis: In patients with Child-Turcotte-Pugh (CTP) B and C cirrhosis and high-risk varices, the combination of and (EVL) is superior to either therapy alone. The CAVARLY trial (N=330) demonstrated that this combination reduced the incidence of first variceal bleed by 62.9% compared to EVL alone (HR 0.37, 95% CI 0.192 to 0.716, p<0.003) ^[38]^A1b.
Secondary Prophylaxis: Pharmacologic treatment (e.g., plus ) may offer superior protection against community-acquired SBP compared to endoscopic sclerotherapy or ligation alone. One study reported a 1-year probability of community-acquired SBP of 1% in the medication group versus 10% in the endoscopic group (p=0.02) ^[132]^B2b.
Junctional Varices: EVL is a viable alternative to cyanoacrylate injection for bleeding junctional varices, with lower rates of long-term complications including SBP ^[136]^A1b.

Step 3: Transjugular Intrahepatic Portosystemic Shunt (TIPS)

TIPS placement addresses the underlying driver of SBP, portal , by mechanically reducing the hepatic venous pressure gradient (HVPG).

Portal Vein Thrombosis (PVT): TIPS is highly effective for recanalizing the portal venous system in patients with non-tumoral PVT, with a 24-month survival rate of 81% ^[83]^B2b.
Infection Risk: While TIPS reduces portal pressure, it does not eliminate SBP risk; follow-up studies show SBP can still occur in approximately 3% of patients post-procedure ^[83]^B2b.

Drug and Modality Comparison

Modality	Indication	Key Outcome	Evidence Level
EVL +	Primary prophylaxis (CTP B/C)	62.9% reduction in first bleed vs EVL alone ^[38]^A1b	1b
Early TIPS	Acute variceal bleed (CTP B/C)	15% absolute risk reduction in 6-week mortality ^[130]^A1b	1b
Short-course PPI	Post-EVL (10 days)	Reduced esophageal ulcer size ^[135]^D5	1a

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Carvedilol vs EVL for Primary Prophylaxis	Baveno VII / BSG: Carvedilol is preferred as it achieves higher hemodynamic response and reduces decompensation ^[137]^D5.	Meta-analysis (Almeida et al.): No significant difference in all-cause mortality or SBP rates between the two ^[131]^A1a.	Moderate	Carvedilol is a non-invasive alternative where endoscopy is impractical ^[131]^A1a.
PPI Use in Cirrhosis	Short-term (10 days): Recommended post-EVL to reduce ulcer size ^[135]^D5.	Long-term: Discouraged due to retrospective data showing increased SBP incidence ^[135]^D5.	Strong	Avoid prolonged PPI use unless a clear indication (e.g., GERD) exists.

Pearl: Prioritize early diagnostic paracentesis (within 24 hours of admission) for all patients with ascites, as every hour of delay in SBP diagnosis increases mortality risk ^[128]^A1c.

Procedural Dosing and Adjustments

Starting Dose	Target / Max Dose	Key Monitoring
6.25 mg daily	12.5 mg daily	Arterial blood pressure, HR ^[137]^D5
20 mg daily	20 mg daily	Liver enzymes, CK (for myopathy) ^[36]^A1b
500 mg daily	500 mg daily	Renal function, QTc interval ^[128]^A1c
400 mg daily	400 mg daily	Local resistance patterns ^[128]^A1c

History and Evolution of Treatment

▸Short-course antibiotic therapy (5 days) is as effective as traditional 10-day courses for SBP resolution.
▸Intravenous albumin infusion (1.5 g/kg at diagnosis, 1 g/kg on day 3) is mandatory to prevent renal impairment and reduce mortality.
▸Primary prophylaxis with fluoroquinolones is indicated for patients with ascitic protein <1.5 g/L and advanced liver or renal dysfunction.

HY High Yield: The 'Sort Criteria' for albumin: The landmark 1999 trial showed the greatest benefit in patients with baseline serum creatinine >1.0 mg/dL or bilirubin >4 mg/dL [144].

The therapeutic timeline for managing spontaneous bacterial peritonitis (SBP) has transitioned from reactive, high-mortality interventions to a structured framework of rapid diagnosis, targeted volume expansion, and evidence-based prophylaxis. Early relied on prolonged courses of intravenous , but the recognition of renal failure as the primary driver of mortality led to the integration of and selective intestinal decontamination as standard care.

Evolution of Antibiotic Therapy

Historically, SBP was treated with 10-day courses of intravenous antibiotics. In 1991, a landmark trial demonstrated that a 5-day course of (2 g every 8 hours) was as efficacious as a 10-day course, achieving comparable bacteriologic cure rates (93.1% vs. 91.2%) and infection-related mortality (0% vs. 4.3%) while significantly reducing costs ^[140]^A1b. Subsequent efforts to simplify therapy showed that oral was as effective as intravenous for uncomplicated SBP, with both groups achieving resolution rates of approximately 84% to 85% ^[139]^A1b. Modern practice now utilizes response-guided therapy; a 2023 validation study confirmed that , , and remain efficacious as initial empirical agents, particularly in community-acquired cases ^[98]^A1b.

The Albumin Breakthrough

The most significant reduction in SBP mortality occurred with the introduction of intravenous . A pivotal 1999 trial established that adding (1.5 g/kg at diagnosis and 1 g/kg on day 3) to reduced the incidence of renal impairment from 33% to 10% (P=0.002) ^[144]^A1b. This intervention lowered hospital mortality from 29% to 10% (P=0.01) and 3-month mortality from 41% to 22% (P=0.03) ^[144]^A1b. While is now a standard of care for SBP, its benefit does not necessarily extend to non-SBP infections, where it improves circulatory function but may not reduce in-hospital mortality ^[40]^A1b.

Development of Prophylactic Strategies

The concept of selective intestinal decontamination emerged in the early 1990s to prevent translocation of aerobic gram-negative bacilli.

Primary Prophylaxis: In patients with low ascitic protein (<15 g/L) and advanced liver failure, reduced the 1-year probability of SBP from 61% to 7% and improved 1-year survival from 48% to 60% ^[32]^A1b. A meta-analysis confirmed that fluoroquinolones reduce the risk of the first SBP episode (OR 0.18, 95% CI 0.09-0.35) and overall mortality (OR 0.60, 95% CI 0.37-0.97) ^[118]^A1a.
Secondary Prophylaxis: 400 mg daily became the standard for preventing recurrence ^[32]^A1b. Recent data suggest that weekly is non-inferior to daily , with comparable 1-year transplant-free survival (73.7% vs. 72.7%) ^[39]^A1b.
Cirrhotic Hemorrhage: For patients with bleeding, intravenous (1 g/day) proved superior to oral , reducing the probability of SBP or bacteremia from 12% to 2% ^[33]^A1b.

Abandoned and Emerging Approaches

Several interventions once considered promising have been abandoned or refined based on trial data. Extracorporeal liver support via fractionated plasma separation and adsorption (FPSA) failed to improve 90-day survival in acute-on-chronic liver failure (47% vs. 38%, P=0.35) ^[35]^A1b. While is well-tolerated, a 2025 trial found it did not improve 12-month survival as primary prophylaxis compared to placebo ^[60]^A1b. Conversely, non-selective beta-blockers like and have gained traction; has been shown to reduce the incidence of complicated (38.5% vs. 67.3%) and improve 1-year survival ^[37]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Primary Prophylaxis	Recommended for ascitic protein <1.5 g/dL with renal/liver failure ^[32]^A1b^[128]^A1c	Weak evidence; concerns over quinolone resistance ^[60]^A1b^[126]^A1a	Moderate	Use is often restricted to "high-risk" subsets
Albumin in non-SBP	Improves ACLF resolution and nosocomial infection rates ^[40]^A1b	No significant mortality benefit in non-SBP infections ^[40]^A1b^[122]^A1c	Low	Albumin is not universally mandated for non-SBP sepsis

Pearl: The addition of albumin to antibiotics remains the single most impactful historical intervention in SBP, reducing the risk of renal failure by 70% and nearly tripling hospital survival rates ^[144]^A1b.

Landmark Trials in SBP Management

Trial Focus	Intervention	Key Outcome	Reference
Antibiotic Duration	5 vs. 10 days Cefotaxime	No difference in cure (93% vs. 91%)	^[140]^A1b
Volume Expansion	Albumin + Cefotaxime	Reduced mortality (29% to 10%)	^[144]^A1b
Primary Prophylaxis	Norfloxacin vs. Placebo	Reduced SBP (61% to 7%)	^[32]^A1b
Hemorrhage Prophylaxis	Ceftriaxone vs. Norfloxacin	Ceftriaxone superior (2% vs. 12% SBP)	^[33]^A1b

Complications

▸Renal impairment is the most critical complication of SBP, but its incidence is significantly reduced by timely albumin infusion.
▸Proton pump inhibitor (PPI) use is an independent risk factor for SBP, with high-dose therapy nearly doubling the risk of infection.
▸SBP increases the 1-month mortality risk four-fold in patients with cirrhosis, necessitating aggressive surveillance for systemic sepsis.

! Warning: Avoid unnecessary proton pump inhibitors in patients with ascites, as their use is associated with a 4.31-fold increased risk of developing SBP [53].

HY High Yield: In patients with SBP, the development of renal failure is the strongest predictor of mortality. Albumin should be administered at 1.5 g/kg on day 1 and 1.0 g/kg on day 3 [156].

The development of spontaneous bacterial peritonitis (SBP) marks a critical transition in the natural history of cirrhosis, often precipitating a cascade of systemic organ failures. While historical mortality rates were higher, contemporary inpatient mortality for SBP has decreased significantly, though it remains a potent driver of poor outcomes ^[154]^B2c^[119]^B2a.

Systemic and Renal Sequelae

Renal impairment is the most frequent and severe complication of SBP, often manifesting as or acute kidney injury (AKI). The systemic inflammatory response triggered by bacterial translocation leads to profound arterial vasodilation and subsequent renal hypoperfusion ^[4]^D5^[106]^B2b.

Renal Failure: SBP is a major precipitant of AKI. Human infusion (1.5 g/kg at diagnosis and 1.0 g/kg on day 3) is established to reduce the incidence of renal impairment (OR 0.63) and significantly decrease mortality in patients with SBP (OR 0.36) ^[156]^A1a.
Hepatic Encephalopathy: Systemic inflammation and nitrogenous waste accumulation frequently trigger or worsen . Rifaximin 550 mg twice daily, often used for HE, has been shown to reduce the risk of developing SBP (aHR 0.210 in non-HCC cohorts) ^[160]^B3b^[69]^B3b.
Acute-on-Chronic Liver Failure (ACLF): SBP is a primary precipitant of ACLF. In patients with ACLF, SBP is independently associated with a poor prognosis ^[35]^A1b.

Portal Hypertensive Complications

SBP is both a consequence and a driver of worsening . The inflammatory state can exacerbate existing varices or lead to new decompensating events ^[106]^B2b.

Variceal Bleeding: There is a bidirectional relationship between SBP and hemorrhage. Prophylactic in the setting of variceal bleeding reduce the risk of SBP (RR 0.29) and overall mortality (RR 0.79) ^[71]^A1a.
Portal Vein Thrombosis: While SBP can occur in the setting of , treatment with (TIPS) for portal complications can achieve complete recanalization in 57% of patients ^[83]^B2b.

Complication Summary Table

Complication	Frequency/Risk	Prevention/
Renal Impairment	High risk in SBP	IV infusion ^[156]^A1a
Hepatic Encephalopathy	Common sequela	, ^[160]^B3b
Variceal Rebleeding	Increased post-SBP	or + EVL ^[65]^D5^[131]^A1a
Sepsis/Bacteremia	30% 1-month mortality	Rapid antibiotic initiation ^[119]^B2a

Iatrogenic and Medication-Related Risks

Pharmacological management of other cirrhotic complications can inadvertently increase SBP risk. (PPIs) are strongly associated with SBP (OR 4.31), likely due to gastric acid suppression allowing for bacterial overgrowth and translocation ^[53]^B3b^[158]^D5. High-dose PPI use (mean defined daily dose ≥0.5) is independently associated with an increased risk of SBP (aHR 1.87) and higher overall mortality (aHR 1.71) ^[157]^B3b. Conversely, certain agents like 300 mg have shown potential in reducing SBP recurrence (HR 0.25) by limiting bacterial translocation ^[64]^A1b.

Pearl: Renal failure is the primary driver of mortality in SBP; early administration of IV albumin (1.5 g/kg) reduces renal impairment and improves survival ^[156]^A1a.

Impact of Prophylactic Interventions on SBP and Mortality

Intervention	Outcome	Effect Size (RR/HR)	Source
Albumin (in SBP)	Mortality	OR 0.36	^[156]^A1a
Antibiotics (in GI Bleed)	SBP Incidence	RR 0.29	^[71]^A1a
Rifaximin (in HE)	SBP Incidence	aHR 0.21	^[160]^B3b
Allopurinol 300mg	SBP Recurrence	HR 0.25	^[64]^A1b
Simvastatin 20mg	SBP Incidence	sHR 0.30	^[36]^A1b

Prognosis & Natural History

▸Infection increases the risk of death 4-fold in patients with cirrhosis, with 1-year mortality reaching 66%.
▸Renal dysfunction and lack of infection resolution are the primary drivers of in-hospital mortality.

HY High Yield: The 1-year mortality after a first episode of SBP is approximately 66%, making these patients immediate candidates for liver transplantation evaluation [17, 119].

! Warning: Antibiotic resistance increases nearly 11-fold in patients on secondary prophylaxis who develop recurrent episodes [66].

Survival in cirrhosis is dictated by the transition through distinct clinical stages, where the development of ascitic infection marks a pivot toward further decompensation. Median survival drops from more than 15 years in compensated cirrhosis to 2 years upon decompensation, and further declines to 9 months once patients reach the further decompensated stage ^[97]^D5. The occurrence of infection increases mortality 4-fold in this population ^[19]^D5^[119]^B2a.

Mortality and Recurrence Dynamics

Untreated or hospital-acquired infection carries a dismal prognosis, with approximately 25% of patients dying within three months and 66.2% within one year ^[14]^A1a^[119]^B2a. Even with standard treatment, in-hospital mortality remains high, particularly in those with elevated liver or renal severity scores ^[67]^B3b.

Short-term Mortality: Overall median mortality for infected patients is 30.3% at 1 month ^[119]^B2a.
Recurrence Risk: Recurrence is frequent; in a national cohort, 16.7% of veterans developed one episode, while 2.3% experienced two and 0.8% had three or more ^[66]^B3b.
Impact of Recurrence: Mortality risk increases with each subsequent episode. Patients on secondary prophylaxis had a 28% higher mortality risk with additional recurrences compared to those without ^[66]^B3b.

Predictors of Poor Outcome

Renal dysfunction is the most critical independent predictor of mortality ^[80]^B2a. The mortality rate among patients who develop (AKI) is 34%, compared to 7% in those without AKI ^[2]^B2b.

Renal Recovery: Mortality is 80% for those without renal recovery, 40% with partial recovery, and 15% with complete recovery ^[2]^B2b.
Clinical Scores: High , scores, and serum lactate levels (>4.9 mmol/L) are significantly associated with increased hospital mortality ^[45]^B3b^[98]^A1b.
Treatment Delay: Each hour of delay in administering appropriate antimicrobial therapy increases hospital mortality by 1.86 times ^[45]^B3b.

Impact of Prophylaxis on Survival

Prophylactic strategies significantly alter the natural history by delaying complications and improving short-term survival ^[32]^A1b^[41]^A1a.

Intervention	Survival Impact	Effect Size (95% CI)	NNT
Oral (Primary)	Improved 3-month survival	RR 0.28 (0.12-0.68) ^[41]^A1a	9 ^[41]^A1a
(Primary)	Improved 1-year survival	60% vs 48% (P=0.05) ^[32]^A1b	9 ^[32]^A1b
Infusion	Reduced mortality	OR 0.34 (0.19-0.60) ^[42]^A1a	5 ^[42]^A1a
(Post-bleed)	Improved 24-month survival	HR 0.48 (0.29-0.81) ^[36]^A1b	8 ^[36]^A1b

While prophylaxis improves survival, it is associated with increased antibiotic resistance. Resistance rates increase significantly with the number of episodes (OR 7.84 for ≥3 vs 2nd episode) and the use of secondary prophylaxis (OR 10.79) ^[66]^B3b.

Pearl: Renal dysfunction is the single most important predictor of death in these patients; the mortality rate reaches 67% in those with renal impairment versus 11% in those with preserved function ^[80]^B2a.

Predictors of In-Hospital Mortality

Predictor	Significance	Mortality Rate/Effect
Renal Dysfunction	Most important variable ^[80]^B2a	67% vs 11% ^[80]^B2a
Irreversible AKI	10-fold mortality increase ^[2]^B2b	80% mortality ^[2]^B2b
MELD Score	Independent predictor ^[80]^B2a	Significant for survival ^[98]^A1b
Treatment Delay	Time-dependent ^[45]^B3b	OR 1.86 per hour delay ^[45]^B3b
SBP Resolution	Primary endpoint ^[98]^A1b	Significant for survival ^[98]^A1b

Special Populations & Pregnancy

▸Pediatric SBP management requires weight-based dosing and intensive nutritional support to optimize transplant outcomes.
▸Pregnancy necessitates the avoidance of fluoroquinolones in favor of third-generation cephalosporins to protect fetal development.
▸Critically ill patients with high severity scores (CLIF-SOFA ≥7) benefit from empirical carbapenem therapy over standard cephalosporins.

HY High Yield: In patients with a history of PPI use, the risk of SBP is significantly elevated; those who have not taken PPIs in the past 90 days are 70% less likely to develop SBP than recent users [20].

! Warning: Irreversible acute kidney injury in the setting of SBP carries a 34% 30-day mortality rate, emphasizing the need for early albumin administration [2, 42].

of spontaneous bacterial peritonitis (SBP) requires specific adjustments in populations where standard diagnostic thresholds or therapeutic regimens may be altered by physiological changes or comorbid complexity. While the core diagnostic criterion of an ascitic polymorphonuclear (PMN) cell count >250/mm³ remains the standard, the choice of and the use of adjuncts like must be tailored to the patient's age, pregnancy status, and immune profile ^[98]^A1b^[153]^D5.

Pediatrics

End-stage liver disease in children presents unique medical and psychosocial challenges, though complications like SBP mirror adult presentations ^[153]^D5.

Diagnostic Considerations: remains the gold standard. Clinicians must account for smaller ascitic volumes and the potential need for sedation during the procedure to ensure safety ^[153]^D5.
Treatment Modifications: Antibiotic dosing must be strictly weight-based. While third-generation cephalosporins remain first-line, the long-term impact of prophylactic fluoroquinolones on developing cartilage and the microbiome is a significant concern ^[153]^D5.
Nutritional Impact: Children are especially vulnerable to nutritional compromise during infection, which can severely impact survival both before and after ^[153]^D5.

Pregnancy

SBP in pregnancy is a critical event requiring a multidisciplinary approach involving hepatology and high-risk obstetrics.

Drug Safety: Ceftriaxone (1 g/day) or are generally preferred due to their established safety profiles in pregnancy ^[98]^A1b^[167]^A1a. Fluoroquinolones like or are typically avoided unless no safer alternative exists, due to potential risks to fetal bone development ^[167]^A1a.
Albumin Use: The use of IV is essential to prevent (AKI), which occurs in approximately 30.6% of SBP patients without albumin support ^[42]^A1a. In pregnancy, maintaining effective arterial blood volume is vital for placental perfusion ^[97]^D5.
Delivery Planning: Active SBP is not an absolute contraindication to vaginal delivery, but the systemic inflammatory response may trigger ^[48]^B2b.

Elderly

Elderly patients often present with higher medical complexity and a greater burden of comorbidities, which influences SBP outcomes ^[154]^B2c.

Risk Profile: Inpatient mortality for cirrhosis has decreased over time, but sepsis remains a primary driver of death in the elderly ^[154]^B2c.
Renal Sensitivity: The risk of AKI is high; irreversible AKI is associated with a 10-fold increase in 30-day mortality compared to those without AKI (34% vs 7%) ^[2]^B2b.
Polypharmacy: Clinicians should prioritize withholding (PPIs), as pharmacologic acid suppression is significantly associated with an increased risk of SBP ^[20]^B3b^[158]^D5.

Immunocompromised

Patients with concomitant immunosuppression (e.g., HIV, post-transplant, or those on chronic steroids) exhibit altered inflammatory responses ^[113]^B2b.

Atypical Presentation: These patients may not mount a significant fever or leukocytosis. A high index of suspicion is required, and the threshold for paracentesis should be low ^[165]^D5.
Microbial Shift: There is a higher prevalence of Gram-positive organisms, including spp. and multidrug-resistant (MDR) bacteria ^[44]^C4^[170]^B2b. In critically ill patients with high CLIF- scores (≥7), empirical treatment with has shown lower in-hospital mortality (23.1%) compared to third-generation cephalosporins (38.8%; aOR 0.84) ^[59]^B3b.

Pearl: In critically ill or immunocompromised patients with a CLIF-SOFA score ≥7, empirical should be prioritized over cephalosporins to reduce in-hospital mortality ^[59]^B3b.

Antibiotic Selection in Special Populations

Population	Preferred Agent	Rationale
Pregnancy	Ceftriaxone	Established safety profile; avoids fetal cartilage risks of quinolones ^[167]^A1a.
Pediatrics		Weight-based dosing; standard first-line for community-acquired SBP ^[153]^D5.
Critically Ill (CLIF-SOFA ≥7)		Superiority over cephalosporins in reducing mortality in high-severity cases ^[59]^B3b.
Quinolone-Allergic		Acceptable alternative if not previously on quinolone prophylaxis ^[165]^D5.

Prevention, Screening & Surveillance

▸Primary prophylaxis with fluoroquinolones or rifaximin is indicated for patients with low-protein ascites (<1.5 g/dL) and advanced liver or renal dysfunction.
▸Secondary prophylaxis is mandatory after the first SBP episode due to a 70% annual recurrence rate.
▸Combination therapy of carvedilol and variceal band ligation is superior to monotherapy for preventing the first variceal bleed in Child-Pugh B/C patients.

HY High Yield: In patients with advanced cirrhosis (Child-Pugh B/C), the combination of carvedilol and VBL reduces 1-year mortality (6.3% vs 20% for carvedilol alone, p=0.012) [38].

Following the of acute complications in , long-term strategies must focus on preventing the high recurrence rate of spontaneous bacterial peritonitis (SBP) and identifying high-risk candidates for primary prophylaxis. Prevention hinges on selective intestinal decontamination to reduce bacterial translocation, alongside rigorous surveillance for decompensation markers.

Primary Prophylaxis

Primary prevention is indicated for patients with advanced liver disease who have not yet experienced SBP but meet specific high-risk criteria. According to AGA and AASLD standards, prophylaxis is recommended for patients with ascitic fluid protein <1.5 g/dL and at least one of the following ^[32]^A1b^[118]^A1a:

≥9 with serum bilirubin ≥3 mg/dL.
Impaired renal function: Serum creatinine ≥1.2 mg/dL, blood urea nitrogen ≥25 mg/dL, or serum sodium ≤130 mEq/L.

In this population, daily reduced the 1-year probability of developing SBP from 61% to 7% (p < 0.001) and improved 1-year survival from 48% to 60% ^[32]^A1b. Meta-analysis confirms that fluoroquinolone prophylaxis reduces the risk of the first SBP episode (OR 0.18) and overall mortality (OR 0.60) ^[118]^A1a. Alternating regimens using and (550 mg twice daily) may offer superior efficacy over monotherapy (74.7% vs 56.4% success rate, p < 0.048) ^[172]^A1b^[173]^A1b.

Secondary Prophylaxis and Recurrence

Patients who survive an initial episode of SBP face a recurrence rate of approximately 70% within one year without intervention. Secondary prophylaxis with daily oral is mandatory and typically lifelong or until ^[174]^A1a. is effective for secondary prevention, with an odds ratio for recurrence of 0.022 (95% CrI 0.00011-0.73) ^[174]^A1a.

Screening and Surveillance

Quality improvement (QI) initiatives emphasize systematic screening for complications in all patients with cirrhosis. Surveillance protocols should include ^[151]^D5^[176]^D5:

Ascitic Fluid Analysis: Diagnostic for any patient with new-onset or clinical deterioration (fever, abdominal pain, or encephalopathy).
Variceal Screening: Endoscopic screening for ; in B or C patients with high-risk varices, combining with endoscopic variceal band ligation (VBL) reduces first-bleed incidence by 62.9% compared to VBL alone (HR 0.37, 95% CI 0.192-0.716, p < 0.003) ^[38]^A1b.
Nutritional and Vaccine Status: Regular assessment of nutritional status and completion of the and hepatitis A/B series ^[151]^D5^[153]^D5.

Dietary and Environmental Precautions

To prevent rare but high-mortality infections such as Listeria monocytogenes SBP (which carries a 1-month mortality of 29%), patients with cirrhosis should avoid high-risk foodborne exposures ^[175]^C4.

Avoid: Unpasteurized dairy, deli meats, and raw seafood.

Pearl: Initiate primary SBP prophylaxis in patients with ascitic protein <1.5 g/dL if they also have Child-Pugh ≥9 or renal impairment (Cr ≥1.2 mg/dL), as this reduces 1-year SBP risk from 61% to 7% ^[32]^A1b.

Criteria for SBP Prophylaxis

Category	Criteria	Recommended Agent
Primary Prophylaxis	Ascitic protein <1.5 g/dL AND (Child-Pugh ≥9 OR Cr ≥1.2 mg/dL)	or
Secondary Prophylaxis	Any prior episode of SBP	Daily or
Acute GI Bleed	Any cirrhotic patient with active hemorrhage	IV Ceftriaxone or oral

References

[1]
Garcia-Tsao G, Lim JK. “Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program.” The American journal of gastroenterology (2009). PMID: 19455106 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores), History and Evolution of Treatment, Special Populations & Pregnancy
[2]
Wong F, O'Leary JG, Reddy KR et al.. “New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection.” Gastroenterology (2013). PMID: 23999172 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification (GI Scores), Prognosis & Natural History, Special Populations & Pregnancy
[3]
Stengel S, Quickert S, Lutz P et al.. “Peritoneal Level of CD206 Associates With Mortality and an Inflammatory Macrophage Phenotype in Patients With Decompensated Cirrhosis and Spontaneous Bacterial Peritonitis.” Gastroenterology (2020). PMID: 31982413 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Special Populations & Pregnancy
[4]
Tranah TH, Edwards LA, Schnabl B et al.. “Targeting the gut-liver-immune axis to treat cirrhosis.” Gut (2020). PMID: 33060124 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Complications
[5]
Silvey S, Patel N, Tsai SY et al.. “Higher Rate of Spontaneous Bacterial Peritonitis Recurrence With Secondary Spontaneous Bacterial Peritonitis Prophylaxis Compared With No Prophylaxis in 2 National Cirrhosis Cohorts.” The American journal of gastroenterology (2024). PMID: 39235290 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Long-term & Definitive Medical Management, Special Populations & Pregnancy
[6]
Xu X, Duan Z, Ding H et al.. “Chinese guidelines on the management of ascites and its related complications in cirrhosis.” Hepatology international (2019). PMID: 30656520 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature
[7]
Johnson DA, Katz PO, Armstrong D et al.. “The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus.” Drugs (2017). PMID: 28233274 ↗
L5GUIDELINECited in: Definition, Classification & Nomenclature
[8]
Lizaola-Mayo B, Vargas HE. “Hepatorenal Syndrome-Acute Kidney Injury in Liver Transplantation.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 37625863 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation, Prognosis & Natural History
[9]
Sundaram V, May FP, Manne V et al.. “Effects of Clostridium difficile infection in patients with alcoholic hepatitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2014). PMID: 24681081 ↗
L3OTHERCited in: Definition, Classification & Nomenclature
[10]
Liu C, Zhang L, Zhang S et al.. “Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in China.” BMJ open (2024). PMID: 38991669 ↗
L5TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[11]
Lutz P, Jeffery HC, Jones N et al.. “NK Cells in Ascites From Liver Disease Patients Display a Particular Phenotype and Take Part in Antibacterial Immune Response.” Frontiers in immunology (2019). PMID: 31440239 ↗
L4TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature
[12]
Nieto JC, Sánchez E, Romero C et al.. “Impaired innate immune response of leukocytes from ascitic fluid of patients with spontaneous bacterial peritonitis.” Journal of leukocyte biology (2015). PMID: 26254307 ↗
L4TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature
[13]
Simonis L, Balcar L, Schedlbauer A et al.. “Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non-Acute Decompensation.” Alimentary pharmacology & therapeutics (2025). PMID: 40719565 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Special Populations & Pregnancy
[14]
Iogna Prat L, Wilson P, Freeman SC et al.. “Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis.” The Cochrane database of systematic reviews (2019). PMID: 31524949 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Prognosis & Natural History, Special Populations & Pregnancy
[15]
Pant C, Olyaee M, Gilroy R et al.. “Emergency department visits related to cirrhosis: a retrospective study of the nationwide emergency department sample 2006 to 2011.” Medicine (2015). PMID: 25569646 ↗
L2COHORTCited in: Definition, Classification & Nomenclature
[16]
Chang L, Liu Y, Li H et al.. “Gut microbiome and its metabolites in liver cirrhosis: mechanisms and clinical implications.” Frontiers in cellular and infection microbiology (2025). PMID: 41278477 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Severity, Staging & Risk Stratification (GI Scores)
[17]
Haderer M, Neubert P, Rinner E et al.. “Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases.” Gut (2021). PMID: 33707230 ↗
L4OTHERCited in: Pathophysiology & Mechanism, History and Evolution of Treatment, Prognosis & Natural History
[18]
Scarpellini E, Valenza V, Gabrielli M et al.. “Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed?” The American journal of gastroenterology (2009). PMID: 19844200 ↗
L3OTHERCited in: Pathophysiology & Mechanism, History and Evolution of Treatment, Special Populations & Pregnancy
[19]
Bonnel AR, Bunchorntavakul C, Reddy KR. “Immune dysfunction and infections in patients with cirrhosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2011). PMID: 21397731 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Prognosis & Natural History
[20]
Goel GA, Deshpande A, Lopez R et al.. “Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2011). PMID: 22155557 ↗
L3OTHERCited in: Pathophysiology & Mechanism, Prognosis & Natural History, Special Populations & Pregnancy
[21]
Sharma A, Roy A, Premkumar M et al.. “Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial.” Hepatology international (2022). PMID: 35349076 ↗
L2TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism
[22]
Deshpande A, Pasupuleti V, Thota P et al.. “Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis.” Journal of gastroenterology and hepatology (2013). PMID: 23190338 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism
[23]
Bendtsen F, Grønbaek H, Hansen JB et al.. “Treatment of ascites and spontaneous bacterial peritonitis - part I.” Danish medical journal (2012). PMID: 22239847 ↗
L1GUIDELINECited in: Pathophysiology & Mechanism
[24]
Kuiper JJ, de Man RA, van Buuren HR. “Review article: Management of ascites and associated complications in patients with cirrhosis.” Alimentary pharmacology & therapeutics (2007). PMID: 18081661 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[25]
Mostafa MS, El-Seidi EA, Kassem AM et al.. “Detection of ascitic fluid infections in patients with liver cirrhosis and ascites.” Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology (2011). PMID: 21429450 ↗
L4TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism
[26]
Huang L, Yu Q, Peng H et al.. “Alterations of gut microbiome and effects of probiotic therapy in patients with liver cirrhosis: A systematic review and meta-analysis.” Medicine (2022). PMID: 36595801 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism
[27]
Raya Tonetti F, Han H, Fondevila MF et al.. “Non-absorbable antibiotics worsen alcohol-associated liver disease in gastric acid-suppressed mice.” Gut microbes (2026). PMID: 42421214 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[28]
Chen J, Zhao H, Méndez-Sánchez N et al.. “Probiotics for the Management of Liver Cirrhosis and Its Complications.” Archives of medical research (2025). PMID: 40913888 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[29]
Song Y, Yang X, Yu C. “Understanding and Treating Hepatorenal Syndrome: Insights from Recent Research.” Seminars in liver disease (2025). PMID: 40169136 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[30]
Markley JD, Bajaj JS. “Rethinking Antibiotic Prophylaxis for Spontaneous Bacterial Peritonitis in Patients With Cirrhosis: First, Do No Harm.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39895304 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[31]
Moreau R, Elkrief L, Bureau C et al.. “Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis.” Gastroenterology (2018). PMID: 30144431 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy
[32]
Fernández J, Navasa M, Planas R et al.. “Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.” Gastroenterology (2007). PMID: 17854593 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[33]
Fernández J, Ruiz del Arbol L, Gómez C et al.. “Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.” Gastroenterology (2006). PMID: 17030175 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Complications, Prognosis & Natural History, Special Populations & Pregnancy
[34]
Ghany MG, Lok AS, Everhart JE et al.. “Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.” Gastroenterology (2009). PMID: 19766643 ↗
L2RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores), Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Complications
[35]
Kribben A, Gerken G, Haag S et al.. “Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure.” Gastroenterology (2012). PMID: 22248661 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Complications, Prognosis & Natural History
[36]
Rana R, Tabish M, Agarwal S et al.. “Simvastatin Addition to Standard of Care Improves Long-Term Survival in Patients With Cirrhosis After Variceal Bleed: An Open Label Randomized Controlled Trial.” The American journal of gastroenterology (2025). PMID: 40736696 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, Endoscopic & Procedural Management, History and Evolution of Treatment, Complications, Prognosis & Natural History
[37]
Khajuria R, Jindal A, Sharma MK et al.. “Efficacy and Safety of Carvedilol in Cirrhosis Patients With New-Onset Uncomplicated Ascites Without High-Risk Esophageal Varices (CARVE-AS Trial).” The American journal of gastroenterology (2025). PMID: 40689908 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Complications, Prognosis & Natural History, Special Populations & Pregnancy
[38]
Tevethia HV, Pande A, Vijayaraghavan R et al.. “Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the 'CAVARLY TRIAL'.” Gut (2024). PMID: 39067870 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, Endoscopic & Procedural Management, History and Evolution of Treatment, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance
[39]
Yim HJ, Suh SJ, Jung YK et al.. “Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial.” The American journal of gastroenterology (2018). PMID: 29946179 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Complications, Prognosis & Natural History, Special Populations & Pregnancy
[40]
Fernández J, Angeli P, Trebicka J et al.. “Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 31394283 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy
[41]
Saab S, Hernandez JC, Chi AC et al.. “Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis.” The American journal of gastroenterology (2009). PMID: 19277033 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management, Prognosis & Natural History, Special Populations & Pregnancy
[42]
Salerno F, Navickis RJ, Wilkes MM. “Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2012). PMID: 23178229 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Special Populations & Pregnancy
[43]
Jeong JY, Cho JY, Kang D et al.. “Impact of Serious Infection on Mortality of Patients With Chronic Liver Disease: A Nationwide Population-based Cohort Study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40651781 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Special Populations & Pregnancy
[44]
Reuken PA, Pletz MW, Baier M et al.. “Emergence of spontaneous bacterial peritonitis due to enterococci - risk factors and outcome in a 12-year retrospective study.” Alimentary pharmacology & therapeutics (2012). PMID: 22449290 ↗
L4COHORTCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Special Populations & Pregnancy
[45]
Karvellas CJ, Abraldes JG, Arabi YM et al.. “Appropriate and timely antimicrobial therapy in cirrhotic patients with spontaneous bacterial peritonitis-associated septic shock: a retrospective cohort study.” Alimentary pharmacology & therapeutics (2015). PMID: 25703246 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Prognosis & Natural History
[46]
Min YW, Lim KS, Min BH et al.. “Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study.” Alimentary pharmacology & therapeutics (2014). PMID: 25078671 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[47]
Louvet A, Wartel F, Castel H et al.. “Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor.” Gastroenterology (2009). PMID: 19445945 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores)
[48]
Fernández J, Acevedo J, Wiest R et al.. “Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis.” Gut (2017). PMID: 28847867 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Prognosis & Natural History, Special Populations & Pregnancy
[49]
Worlicek M, Knebel K, Linde HJ et al.. “Splanchnic sympathectomy prevents translocation and spreading of E coli but not S aureus in liver cirrhosis.” Gut (2010). PMID: 20519743 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors
[50]
Serper M, Pulaski ME, Zhang S et al.. “Albumin for Spontaneous Bacterial Peritonitis: Care Variation, Disparities, and Outcomes.” The American journal of gastroenterology (2024). PMID: 39530516 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Special Populations & Pregnancy
[51]
Christou L, Pappas G, Falagas ME. “Bacterial infection-related morbidity and mortality in cirrhosis.” The American journal of gastroenterology (2007). PMID: 17509025 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Prevention, Screening & Surveillance
[52]
Bajaj JS, Tandon P, OʼLeary JG et al.. “Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis.” The American journal of gastroenterology (2019). PMID: 30694868 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management, Prognosis & Natural History, Special Populations & Pregnancy
[53]
Bajaj JS, Zadvornova Y, Heuman DM et al.. “Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites.” The American journal of gastroenterology (2009). PMID: 19337238 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Complications
[54]
Ghandour B, Tapper EB, Kaplan DE et al.. “Preoperative Hepatology and Primary Care Visits Improve Postoperative Outcomes in Patients With Cirrhosis Undergoing Surgery.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 38906442 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy
[55]
Mounzer R, Malik SM, Nasr J et al.. “Spontaneous bacterial peritonitis before liver transplantation does not affect patient survival.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2010). PMID: 20417723 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prognosis & Natural History
[56]
Poca M, Concepción M, Casas M et al.. “Role of albumin treatment in patients with spontaneous bacterial peritonitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2011). PMID: 22094025 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management, Special Populations & Pregnancy
[57]
Silvey S, Patel N, Liu J et al.. “A Machine Learning Algorithm Avoids Unnecessary Paracentesis for Exclusion of SBP in Cirrhosis in Resource-limited Settings.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 38906441 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores)
[58]
Simon TG, Patorno E, Schneeweiss S. “Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 34256144 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy
[59]
Kim SW, Yoon JS, Park J et al.. “Empirical Treatment With Carbapenem vs Third-generation Cephalosporin for Treatment of Spontaneous Bacterial Peritonitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2020). PMID: 32623007 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Special Populations & Pregnancy
[60]
Thévenot T, Elkrief L, Bureau C et al.. “Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled trial.” Journal of hepatology (2025). PMID: 40653111 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Complications, Prognosis & Natural History, Special Populations & Pregnancy
[61]
Gupta A, Agarwal S, Sharma S et al.. “Antibiotic prophylaxis to prevent infection in patients with Child-Pugh A cirrhosis with upper gastrointestinal bleed: an open label randomised controlled trial.” Hepatology international (2025). PMID: 39751759 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History
[62]
Ranjan A, Jindal A, Maiwall R et al.. “Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial.” Hepatology international (2024). PMID: 38727780 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History
[63]
Ashritha A, Lal BB, Khanna R et al.. “Midodrine reduces new-onset acute kidney injury and hyponatremia in children with cirrhosis and ascites awaiting liver transplantation: Results from an open-label RCT.” Journal of pediatric gastroenterology and nutrition (2023). PMID: 38374552 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment
[64]
Glal KAM, El-Haggar SM, Abdel-Salam SM et al.. “Allopurinol Prevents Cirrhosis-Related Complications: A Quadruple Blind Placebo-Controlled Trial.” The American journal of medicine (2023). PMID: 37832758 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, Complications
[65]
Li Y, Du L, Zhang S et al.. “Endoscopic variceal ligation combined with carvedilol versus endoscopic variceal ligation combined with propranolol for the treatment of oesophageal variceal bleeding in cirrhosis: study protocol for a multicentre, randomised controlled trial.” BMJ open (2025). PMID: 40288803 ↗
L5TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Endoscopic & Procedural Management, Complications
[66]
Silvey S, Patel N, O'Leary JG et al.. “Spontaneous Bacterial Peritonitis Is Associated With High Mortality, Which Interacts With Antibiotic Prophylaxis in a National Cirrhosis Cohort.” Alimentary pharmacology & therapeutics (2025). PMID: 41423725 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management, Prognosis & Natural History, Special Populations & Pregnancy
[67]
Poca M, Alvarado-Tapias E, Concepción M et al.. “Predictive model of mortality in patients with spontaneous bacterial peritonitis.” Alimentary pharmacology & therapeutics (2016). PMID: 27464682 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores), Prognosis & Natural History, Special Populations & Pregnancy
[68]
Tergast TL, Griemsmann M, Stockhoff L et al.. “Home-based, tunnelled peritoneal drainage system as an alternative treatment option for patients with refractory ascites.” Alimentary pharmacology & therapeutics (2022). PMID: 35656633 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy
[69]
Salehi S, Tranah TH, Lim S et al.. “Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list.” Alimentary pharmacology & therapeutics (2019). PMID: 31169941 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications
[70]
Tergast TL, Kimmann M, Laser H et al.. “Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis.” Alimentary pharmacology & therapeutics (2019). PMID: 31373713 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors
[71]
Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI et al.. “Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding.” The Cochrane database of systematic reviews (2010). PMID: 20824832 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management, Complications, Prognosis & Natural History
[72]
Flamm SL, Wong F, Ahn J et al.. “AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients With Cirrhosis: Expert Review.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022). PMID: 36075500 ↗
L5GUIDELINECited in: Clinical Presentation, History and Evolution of Treatment
[73]
Kumar M, Kainth S, Choudhury A et al.. “Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial.” Hepatology international (2019). PMID: 31541422 ↗
L1RCTCited in: Clinical Presentation, Long-term & Definitive Medical Management
[74]
Wejnaruemarn S, Susantitaphong P, Komolmit P et al.. “Procalcitonin and presepsin for detecting bacterial infection and spontaneous bacterial peritonitis in cirrhosis: A systematic review and meta-analysis.” World journal of gastroenterology (2025). PMID: 39958447 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[75]
Ubhi N, Mourad A, Tausan M et al.. “Outcomes after hospitalisation with spontaneous bacterial peritonitis over a 13-year period: a retrospective cohort study.” European journal of gastroenterology & hepatology (2023). PMID: 36827533 ↗
L3COHORTCited in: Clinical Presentation
[76]
Zhang Q, Shi B, Wu L. “Characteristics and risk factors of infections in patients with HBV-related acute-on-chronic liver failure: a retrospective study.” PeerJ (2022). PMID: 35811816 ↗
L3COHORTCited in: Clinical Presentation, Severity, Staging & Risk Stratification (GI Scores)
[77]
Zheng YB, Huang ZL, Wu ZB et al.. “Dynamic changes of clinical features that predict the prognosis of acute-on-chronic hepatitis B liver failure: a retrospective cohort study.” International journal of medical sciences (2013). PMID: 24151437 ↗
L3COHORTCited in: Clinical Presentation
[78]
Lei Y, Guo Q, Liu J et al.. “Staphylococcus cohnii infection diagnosed by metagenomic next generation sequencing in a patient on hemodialysis with cirrhotic ascites: a case report.” Frontiers in cellular and infection microbiology (2023). PMID: 37808911 ↗
L4CASE_REPORTCited in: Clinical Presentation
[79]
Lopes Correia B, Diniz SE, Lopes da Silva E et al.. “Septic arthritis of the lumbar facet joint presenting as spontaneous bacterial peritonitis: a rare case requiring surgical intervention.” European journal of orthopaedic surgery & traumatology : orthopedie traumatologie (2019). PMID: 31463672 ↗
L4CASE_REPORTCited in: Clinical Presentation, Severity, Staging & Risk Stratification (GI Scores)
[80]
Tandon P, Garcia-Tsao G. “Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2010). PMID: 21145427 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prognosis & Natural History
[81]
Goel A, Rahim U, Nguyen LH et al.. “Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis.” Alimentary pharmacology & therapeutics (2017). PMID: 28994123 ↗
L1SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prognosis & Natural History
[82]
Parsi MA, Saadeh SN, Zein NN et al.. “Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis.” Gastroenterology (2008). PMID: 18590731 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[83]
Luca A, Miraglia R, Caruso S et al.. “Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis.” Gut (2011). PMID: 21357252 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Endoscopic & Procedural Management, Complications, Prognosis & Natural History, Special Populations & Pregnancy
[84]
Thévenot T, Briot C, Macé V et al.. “The Periscreen Strip Is Highly Efficient for the Exclusion of Spontaneous Bacterial Peritonitis in Cirrhotic Outpatients.” The American journal of gastroenterology (2016). PMID: 27619833 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[85]
Tandon P, Delisle A, Topal JE et al.. “High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2012). PMID: 22902776 ↗
L3OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[86]
Nguyen-Khac E, Cadranel JF, Thevenot T et al.. “Review article: the utility of reagent strips in the diagnosis of infected ascites in cirrhotic patients.” Alimentary pharmacology & therapeutics (2008). PMID: 19086234 ↗
L2REVIEW_NARRATIVECited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[87]
Engelmann C, Schob S, Nonnenmacher I et al.. “Loss of paraspinal muscle mass is a gender-specific consequence of cirrhosis that predicts complications and death.” Alimentary pharmacology & therapeutics (2018). PMID: 30417398 ↗
L3OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), History and Evolution of Treatment
[88]
Yendewa GA, Elangovan A, Olasehinde T et al.. “Impact of hepatic steatosis on mortality, hepatocellular carcinoma, end-stage liver disease and HBsAg seroclearance in chronic hepatitis B: a United States cohort study.” Frontiers in immunology (2025). PMID: 40255390 ↗
L3COHORTCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Pregnancy
[89]
Sbeit W, Maamoun B, Azzam S et al.. “Ascites fluid calprotectin level is highly accurate in diagnosing spontaneous bacterial peritonitis: a preliminary proof of concept prospective study.” Clinical and experimental medicine (2024). PMID: 38281236 ↗
L2COHORTCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[90]
Tang TH, Lin CM, Niu KY et al.. “Comparison of the Diagnostic Accuracies of Procalcitonin and C-Reactive Protein for Spontaneous Bacterial Peritonitis in Patients with Cirrhosis: A Systematic Review and Meta-Analysis.” Medicina (Kaunas, Lithuania) (2025). PMID: 40731765 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[91]
Wong ZY, Koh JH, Muthiah M et al.. “Proton Pump Inhibitors Increases Longitudinal Risk of Mortality, Decompensation, and Infection in Cirrhosis: A Meta-Analysis.” Digestive diseases and sciences (2023). PMID: 37968557 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[92]
Seyedi SA, Nabipoorashrafi SA, Hernandez J et al.. “Neutrophil to Lymphocyte Ratio and Spontaneous Bacterial Peritonitis among Cirrhotic Patients: A Systematic Review and Meta-analysis.” Canadian journal of gastroenterology & hepatology (2022). PMID: 36204262 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[93]
Hadjivasilis A, Tzanis A, Ioakim KJ et al.. “The diagnostic accuracy of ascitic calprotectin for the early diagnosis of spontaneous bacterial peritonitis: systematic review and meta-analysis.” European journal of gastroenterology & hepatology (2021). PMID: 32541235 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[94]
Dibas M, Rajab AM, Zaghloul MS et al.. “Ascitic calprotectin for the diagnosis of spontaneous bacterial peritonitis: a systematic review and meta-analysis.” European journal of gastroenterology & hepatology (2020). PMID: 32175980 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[95]
Wang C, Zhang H, Liu J. “The diagnostic efficacy of metagenomic next-generation sequencing in spontaneous bacterial peritonitis: System review and meta-analysis.” Gastroenterologia y hepatologia (2025). PMID: 40294646 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[96]
Henney AE, Wilson J, Riley DR et al.. “Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri-Menopausal MASLD.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 41731345 ↗
L3OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[97]
Garcia-Tsao G, Abraldes JG, Rich NE et al.. “AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.” Gastroenterology (2023). PMID: 37978969 ↗
L5GUIDELINECited in: Severity, Staging & Risk Stratification (GI Scores), Acute Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy
[98]
Yim HJ, Kim TH, Suh SJ et al.. “Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP.” The American journal of gastroenterology (2023). PMID: 36594820 ↗
L1RCTCited in: Severity, Staging & Risk Stratification (GI Scores), Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy
[99]
Klein S, Rick J, Lehmann J et al.. “Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.” Gut (2015). PMID: 26385087 ↗
L4OTHERCited in: Severity, Staging & Risk Stratification (GI Scores), Endoscopic & Procedural Management
[100]
Yip TC, Chan HL, Tse YK et al.. “On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis.” The American journal of gastroenterology (2018). PMID: 30315283 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification (GI Scores), Complications
[101]
Obstein KL, Campbell MS, Reddy KR et al.. “Association between model for end-stage liver disease and spontaneous bacterial peritonitis.” The American journal of gastroenterology (2007). PMID: 17714556 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification (GI Scores), History and Evolution of Treatment
[102]
Kim JJ, Tsukamoto MM, Mathur AK et al.. “Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis.” The American journal of gastroenterology (2014). PMID: 25091061 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores)
[103]
Rosenblatt R, Tafesh Z, Shen N et al.. “Early Paracentesis in High-Risk Hospitalized Patients: Time for a New Quality Indicator.” The American journal of gastroenterology (2019). PMID: 31688022 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores)
[104]
Tandon P, Kumar D, Seo YS et al.. “The 22/11 risk prediction model: a validated model for predicting 30-day mortality in patients with cirrhosis and spontaneous bacterial peritonitis.” The American journal of gastroenterology (2013). PMID: 23877350 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification (GI Scores)
[105]
Wang J, Wu Y, Bi Q et al.. “Adverse outcomes of proton pump inhibitors in chronic liver disease: a systematic review and meta-analysis.” Hepatology international (2020). PMID: 31912308 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification (GI Scores)
[106]
Mandorfer M, Schwabl P, Paternostro R et al.. “Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity.” Alimentary pharmacology & therapeutics (2018). PMID: 29377193 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores), Complications
[107]
Sasso R, Rockey DC. “Non-selective beta-blocker use in cirrhotic patients is associated with a reduced likelihood of hospitalisation for infection.” Alimentary pharmacology & therapeutics (2020). PMID: 33314175 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification (GI Scores)
[108]
Chan CW, Tsochatzis EA, Carpenter JR et al.. “Predicting the advent of ascites and other complications in primary biliary cirrhosis: a staged model approach.” Alimentary pharmacology & therapeutics (2009). PMID: 20003096 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores), Complications
[109]
Cartier M, Terg R, Lucero R et al.. “Pilot study: Gelafundin (polygeline) 4% plus antibiotics in the treatment of high-risk cirrhotic patients with spontaneous bacterial peritonitis.” Alimentary pharmacology & therapeutics (2010). PMID: 20345510 ↗
L4OTHERCited in: Severity, Staging & Risk Stratification (GI Scores), Long-term & Definitive Medical Management
[110]
Yin X, Qin E, Song R et al.. “Diagnostic model for spontaneous bacterial peritonitis in cirrhotic patients with ascites: a multicenter cohort study.” European journal of gastroenterology & hepatology (2024). PMID: 39292981 ↗
L2COHORTCited in: Severity, Staging & Risk Stratification (GI Scores)
[111]
Jiménez-Gutiérrez JM, García-Juárez I, Olivas-Martinez A et al.. “One-year outcome of patients with cirrhosis who developed spontaneous bacterial empyema: A cohort study.” Journal of digestive diseases (2021). PMID: 34738327 ↗
L3COHORTCited in: Severity, Staging & Risk Stratification (GI Scores)
[112]
Tufoni M, Zaccherini G, Caraceni P et al.. “Albumin: Indications in chronic liver disease.” United European gastroenterology journal (2020). PMID: 32213034 ↗
L5CASE_REPORTCited in: Severity, Staging & Risk Stratification (GI Scores)
[113]
Shiffman ML, Morishima C, Dienstag JL et al.. “Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.” Gastroenterology (2009). PMID: 19747918 ↗
L2RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy
[114]
Turnes J, Garcia-Pagan JC, Abraldes JG et al.. “Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis.” The American journal of gastroenterology (2006). PMID: 16542287 ↗
L2RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Complications
[115]
Wong VW, Wong GL, Chim AM et al.. “Surrogate end points and long-term outcome in patients with chronic hepatitis B.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2009). PMID: 19500693 ↗
L2RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Complications
[116]
Angeli P, Guarda S, Fasolato S et al.. “Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost.” Alimentary pharmacology & therapeutics (2006). PMID: 16393283 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History
[117]
Prakash V, Arora V, Jindal A et al.. “Combination of GM CSF and carbapenem is superior to carbapenem monotherapy in difficult-to-treat spontaneous bacterial peritonitis: A randomized controlled trial.” Liver international : official journal of the International Association for the Study of the Liver (2023). PMID: 36748109 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[118]
Loomba R, Wesley R, Bain A et al.. “Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2008). PMID: 19250986 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance
[119]
Arvaniti V, D'Amico G, Fede G et al.. “Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis.” Gastroenterology (2010). PMID: 20558165 ↗
L2OTHERCited in: Long-term & Definitive Medical Management, Complications, Prognosis & Natural History
[120]
Gonzalez SA. “Antibiotic Prophylaxis for Spontaneous Bacterial Peritonitis: Benefit or Risk?” The American journal of gastroenterology (2019). PMID: 30920419 ↗
L5OTHERCited in: Long-term & Definitive Medical Management, Prognosis & Natural History
[121]
Tanaka T, Vander Weg M, Jones MP et al.. “Assessment of the 2021 AASLD Practice Guidance for Albumin Infusion in Elective Therapeutic Paracentesis: A Regression Discontinuity Design.” The American journal of gastroenterology (2024). PMID: 38501671 ↗
L2OTHERCited in: Long-term & Definitive Medical Management
[122]
Callum J, Skubas NJ, Bathla A et al.. “Use of Intravenous Albumin: A Guideline From the International Collaboration for Transfusion Medicine Guidelines.” Chest (2024). PMID: 38447639 ↗
L1GUIDELINECited in: Long-term & Definitive Medical Management, History and Evolution of Treatment
[123]
Tapper EB, Finkelstein D, Mittleman MA et al.. “A Quality Improvement Initiative Reduces 30-Day Rate of Readmission for Patients With Cirrhosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2015). PMID: 26407750 ↗
L2OTHERCited in: Long-term & Definitive Medical Management
[124]
Zeng X, Sheng X, Wang PQ et al.. “Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis.” Hepatology international (2021). PMID: 33385299 ↗
L1RCTCited in: Long-term & Definitive Medical Management
[125]
Frenette C, Kayali Z, Mena E et al.. “Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.” Journal of hepatology (2020). PMID: 33038432 ↗
L1RCTCited in: Long-term & Definitive Medical Management
[126]
Komolafe O, Roberts D, Freeman SC et al.. “Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis.” The Cochrane database of systematic reviews (2020). PMID: 31978256 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History
[127]
Cohen MJ, Sahar T, Benenson S et al.. “Antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding.” The Cochrane database of systematic reviews (2009). PMID: 19370611 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management, Complications, Prognosis & Natural History
[128]
Aithal GP, Palaniyappan N, China L et al.. “Guidelines on the management of ascites in cirrhosis.” Gut (2020). PMID: 33067334 ↗
L1GUIDELINECited in: Endoscopic & Procedural Management, History and Evolution of Treatment
[129]
Lorenzo-Zúñiga V, Rodríguez-Ortigosa CM, Bartolí R et al.. “Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats.” Gut (2006). PMID: 16434425 ↗
L5OTHERCited in: Endoscopic & Procedural Management, Special Populations & Pregnancy
[130]
Lv Y, Yang Z, Liu L et al.. “Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial.” The lancet. Gastroenterology & hepatology (2019). PMID: 31153882 ↗
L1RCTCited in: Endoscopic & Procedural Management
[131]
Almeida LGS, Gonçalves OR, de Oliveira THF et al.. “Carvedilol Versus Endoscopic Variceal Ligation for Prophylaxis of Esophageal Variceal Bleeding in Patients With Liver Cirrhosis: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Journal of clinical gastroenterology (2026). PMID: 42090574 ↗
L1SR_MA_RCTCited in: Endoscopic & Procedural Management, Complications, Prognosis & Natural History
[132]
Gonzalez-Suarez B, Guarner C, Villanueva C et al.. “Pharmacologic treatment of portal hypertension in the prevention of community-acquired spontaneous bacterial peritonitis.” European journal of gastroenterology & hepatology (2006). PMID: 16357619 ↗
L2RCTCited in: Endoscopic & Procedural Management
[133]
Bishnu S, Ahammed SM, Sarkar A et al.. “Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.” European journal of gastroenterology & hepatology (2018). PMID: 29099421 ↗
L1RCTCited in: Endoscopic & Procedural Management
[134]
Mingpun W, Sobanska A, Nimworapan M et al.. “Carvedilol and traditional nonselective beta blockers for the secondary prophylaxis of variceal hemorrhage and portal hypertension related complications among patients with decompensated cirrhosis: a systematic review and network meta-analysis.” Hepatology international (2025). PMID: 40178720 ↗
L1SR_OBSCited in: Endoscopic & Procedural Management, History and Evolution of Treatment
[135]
Lo EA, Wilby KJ, Ensom MH. “Use of proton pump inhibitors in the management of gastroesophageal varices: a systematic review.” The Annals of pharmacotherapy (2015). PMID: 25583938 ↗
L5SR_OBSCited in: Endoscopic & Procedural Management
[136]
El Amin H, Abdel Baky L, Sayed Z et al.. “A randomized trial of endoscopic variceal ligation versus cyanoacrylate injection for treatment of bleeding junctional varices.” Tropical gastroenterology : official journal of the Digestive Diseases Foundation (2010). PMID: 21568143 ↗
L1RCTCited in: Endoscopic & Procedural Management
[137]
Turco L, Reiberger T, Vitale G et al.. “Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.” Liver international : official journal of the International Association for the Study of the Liver (2023). PMID: 36897563 ↗
L5REVIEW_NARRATIVECited in: Endoscopic & Procedural Management
[138]
Soriano G, Guarner C, Teixidó M et al.. “Selective intestinal decontamination prevents spontaneous bacterial peritonitis.” Gastroenterology (1991). PMID: 1985045 ↗
L1RCTCited in: History and Evolution of Treatment
[139]
Navasa M, Follo A, Llovet JM et al.. “Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis.” Gastroenterology (1996). PMID: 8831596 ↗
L1RCTCited in: History and Evolution of Treatment
[140]
Runyon BA, McHutchison JG, Antillon MR et al.. “Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients.” Gastroenterology (1991). PMID: 2019378 ↗
L1RCTCited in: History and Evolution of Treatment
[141]
Soriano G, Guarner C, Tomás A et al.. “Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage.” Gastroenterology (1992). PMID: 1397884 ↗
L1RCTCited in: History and Evolution of Treatment
[142]
Runyon BA, Antillon MR, Montano AA. “Effect of diuresis versus therapeutic paracentesis on ascitic fluid opsonic activity and serum complement.” Gastroenterology (1989). PMID: 2656362 ↗
L1RCTCited in: History and Evolution of Treatment
[143]
Sàbat M, Kolle L, Soriano G et al.. “Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding.” The American journal of gastroenterology (1998). PMID: 9860409 ↗
L1RCTCited in: History and Evolution of Treatment
[144]
Sort P, Navasa M, Arroyo V et al.. “Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.” The New England journal of medicine (1999). PMID: 10432325 ↗
L1RCTCited in: History and Evolution of Treatment
[145]
Liaw YF, Sung JJ, Chow WC et al.. “Lamivudine for patients with chronic hepatitis B and advanced liver disease.” The New England journal of medicine (2004). PMID: 15470215 ↗
L1RCTCited in: History and Evolution of Treatment
[146]
Leport J, Devars Du Mayne JF, Hay JM et al.. “Chylous ascites and encapsulating peritonitis: unusual complications of spontaneous bacterial peritonitis.” The American journal of gastroenterology (1987). PMID: 3578227 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment
[147]
Wongpaitoon V, Sathapatayavongs B, Prachaktam R et al.. “Spontaneous Vibrio vulnificus peritonitis and primary sepsis in two patients with alcoholic cirrhosis.” The American journal of gastroenterology (1985). PMID: 3898820 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment
[148]
Xu X, Ding H, Jia J et al.. “Chinese guidelines on the management of ascites in cirrhosis : Chinese Society of Hepatology, Chinese Medical Association.” Hepatology international (2024). PMID: 38980598 ↗
L1GUIDELINECited in: History and Evolution of Treatment, Complications
[149]
Rosa H, Silvério AO, Perini RF et al.. “Bacterial infection in cirrhotic patients and its relationship with alcohol.” The American journal of gastroenterology (2000). PMID: 10811341 ↗
L3OTHERCited in: History and Evolution of Treatment
[150]
Sierra F, Torres D, Cárdenas A. “The role of likelihood ratio in clinical diagnosis: applicability in the setting of spontaneous bacterial peritonitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2005). PMID: 15645409 ↗
L5OTHERCited in: History and Evolution of Treatment
[151]
Tapper EB. “Building Effective Quality Improvement Programs for Liver Disease: A Systematic Review of Quality Improvement Initiatives.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2016). PMID: 27103114 ↗
L5SR_OBSCited in: Complications, Prevention, Screening & Surveillance
[152]
Dahl E, Gluud LL, Kimer N et al.. “Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.” Alimentary pharmacology & therapeutics (2012). PMID: 22908905 ↗
L1SR_OBSCited in: Complications, Prognosis & Natural History, Special Populations & Pregnancy
[153]
Leonis MA, Balistreri WF. “Evaluation and management of end-stage liver disease in children.” Gastroenterology (2008). PMID: 18471551 ↗
L5REVIEW_NARRATIVECited in: Complications, Prognosis & Natural History, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[154]
Schmidt ML, Barritt AS, Orman ES et al.. “Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010.” Gastroenterology (2015). PMID: 25623044 ↗
L2OTHERCited in: Complications, Special Populations & Pregnancy
[155]
Kanwal F, Kramer JR, Buchanan P et al.. “The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs.” Gastroenterology (2012). PMID: 22465432 ↗
L4OTHERCited in: Complications
[156]
Bai Z, Wang L, Wang R et al.. “Use of human albumin infusion in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials.” Hepatology international (2022). PMID: 36048318 ↗
L1SR_MA_RCTCited in: Complications
[157]
Yoon JS, Hong JH, Park SY et al.. “High-dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study.” Alimentary pharmacology & therapeutics (2024). PMID: 38389319 ↗
L3OTHERCited in: Complications
[158]
Lewis JH, Stine JG. “Review article: prescribing medications in patients with cirrhosis - a practical guide.” Alimentary pharmacology & therapeutics (2013). PMID: 23638982 ↗
L5REVIEW_NARRATIVECited in: Complications, Special Populations & Pregnancy
[159]
Wiegand J, Kühne M, Pradat P et al.. “Different patterns of decompensation in patients with alcoholic vs. non-alcoholic liver cirrhosis.” Alimentary pharmacology & therapeutics (2012). PMID: 22530565 ↗
L3OTHERCited in: Complications
[160]
Kang SH, Lee YB, Lee JH et al.. “Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.” Alimentary pharmacology & therapeutics (2017). PMID: 28836723 ↗
L3OTHERCited in: Complications
[161]
Leache L, Gutiérrez-Valencia M, Saiz LC et al.. “Meta-analysis: Efficacy and safety of albumin in the prevention and treatment of complications in patients with cirrhosis.” Alimentary pharmacology & therapeutics (2022). PMID: 36524316 ↗
L1SR_OBSCited in: Prognosis & Natural History
[162]
Biswas S, Swaroop S, Mehta S et al.. “Early Endovascular Intervention in Combination with Medical Therapy versus Medical Therapy Alone in the Initial Management of Patients with Primary Budd-Chiari Syndrome: A Randomized Controlled Trial.” Journal of vascular and interventional radiology : JVIR (2025). PMID: 41421590 ↗
L1RCTCited in: Prognosis & Natural History
[163]
Biswas S, Mehta S, Swaroop S et al.. “Clinical Outcomes of Intravenous Albumin Administration After Acute Variceal Hemorrhage in Patients with Cirrhosis: An Open-Label, Randomized Controlled Trial.” Digestive diseases and sciences (2025). PMID: 41139775 ↗
L1RCTCited in: Prognosis & Natural History, Special Populations & Pregnancy
[164]
Turco L, Villanueva C, La Mura V et al.. “Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 31176013 ↗
L1SR_OBSCited in: Special Populations & Pregnancy
[165]
Dever JB, Sheikh MY. “Review article: spontaneous bacterial peritonitis--bacteriology, diagnosis, treatment, risk factors and prevention.” Alimentary pharmacology & therapeutics (2015). PMID: 25819304 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[166]
Soriano G, Esparcia O, Montemayor M et al.. “Bacterial DNA in the diagnosis of spontaneous bacterial peritonitis.” Alimentary pharmacology & therapeutics (2010). PMID: 21083594 ↗
L2OTHERCited in: Special Populations & Pregnancy
[167]
Chavez-Tapia NC, Soares-Weiser K, Brezis M et al.. “Antibiotics for spontaneous bacterial peritonitis in cirrhotic patients.” The Cochrane database of systematic reviews (2009). PMID: 19160207 ↗
L1SR_OBSCited in: Special Populations & Pregnancy
[168]
Chen X, Chen W, Zhou J et al.. “Association between early antibiotic treatment after admission and mortality of acute-on-chronic liver failure patients with bacterial infection: A multicenter retrospective study.” Virulence (2025). PMID: 40443157 ↗
L3COHORTCited in: Special Populations & Pregnancy
[169]
Serper M, Tang H, Zhang S et al.. “Clinical outcomes and care for spontaneous bacterial peritonitis: A national cohort study.” Hepatology (Baltimore, Md.) (2025). PMID: 39879583 ↗
L2COHORTCited in: Special Populations & Pregnancy
[170]
Cao Z, Wong F, Choudhury AK et al.. “Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium.” The lancet. Gastroenterology & hepatology (2024). PMID: 39243795 ↗
L2COHORTCited in: Special Populations & Pregnancy
[171]
Ismail A, Abusuliman M, Kloub M et al.. “Comparative Risk of Recurrent Esophageal Variceal Hemorrhage and Other Decompensation Events with Carvedilol Versus Propranolol in Patients with Cirrhosis: A Retrospective Study.” Digestive diseases and sciences (2025). PMID: 41108335 ↗
L3COHORTCited in: Special Populations & Pregnancy
[172]
Assem M, Elsabaawy M, Abdelrashed M et al.. “Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study.” Hepatology international (2015). PMID: 26660707 ↗
L1RCTCited in: Prevention, Screening & Surveillance
[173]
Ibrahim ES, Alsebaey A, Zaghla H et al.. “Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome.” European journal of gastroenterology & hepatology (2017). PMID: 28902040 ↗
L1RCTCited in: Prevention, Screening & Surveillance
[174]
Soni H, Kumar-M P, Sharma V et al.. “Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis.” Hepatology international (2020). PMID: 32266675 ↗
L1SR_OBSCited in: Prevention, Screening & Surveillance
[175]
Blanchard F, Henry B, Vijayaratnam S et al.. “Listeria monocytogenes-associated spontaneous bacterial peritonitis in France: a nationwide observational study of 208 cases.” The Lancet. Infectious diseases (2024). PMID: 38608698 ↗
L4OTHERCited in: Prevention, Screening & Surveillance
[176]
James J, Liou IW. “Comprehensive Care of Patients with Chronic Liver Disease.” The Medical clinics of North America (2015). PMID: 26320039 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance

Spontaneous Bacterial Peritonitis

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

Synonyms and Nomenclature

Clinical Classification

Clinical Significance

Pathophysiology & Mechanism

Luminal Dysbiosis and Microbial Shifts

Intestinal Barrier Failure

Cirrhosis-Associated Immune Dysfunction (CAID)

Role of Gastric Acid Suppression

Mechanism Flowchart

Controversies and Guideline Disagreement

Epidemiology, Etiology & Risk Factors

Incidence and Prevalence

Modifiable and Clinical Risk Factors

Risk Factor Summary Table

Clinical Presentation

Presenting Symptoms

Physical Examination Findings

Phenotypic Variants

Red Flags

Atypical Presentations

Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)

Gold-Standard Test: Ascitic Fluid Analysis

Laboratory Studies and Biomarkers

Imaging and Endoscopy

Diagnostic Algorithm

Controversies and Guideline Disagreement

Severity, Staging & Risk Stratification (GI Scores)

Validated Prognostic Scoring Systems

Renal Function and Mortality Risk

Biomarkers and Novel Stratification Tools

Impact of Procedural Timing

Acute Management

Step 1: Immediate Empirical Antibiotic Initiation

Step 2: Intravenous Albumin for Renal Protection

Step 3: Response Assessment and Monitoring

Step 4: Management of Concurrent Complications

Drug / Modality Comparison Table

Dosing Table

Treatment Failure Protocol

What NOT to Do

Controversies and Guideline Disagreement

Long-term & Definitive Medical Management

Step 1: Risk Stratification for Primary Prophylaxis

Step 2: Secondary Prophylaxis and Recurrence Prevention

Step 3: Optimization of Portal Hemodynamics and Adjunctive Therapy

Step 4: Management of Treatment Non-Response

Step 5: Definitive Disposition

Controversies and Guideline Disagreement

Dosing Table for Long-term Management

Endoscopic & Procedural Management

Step 1: Diagnostic and Therapeutic Paracentesis

Step 2: Endoscopic Variceal Management

Step 3: Transjugular Intrahepatic Portosystemic Shunt (TIPS)

Drug and Modality Comparison

Controversies and Guideline Disagreement

History and Evolution of Treatment

Evolution of Antibiotic Therapy

The Albumin Breakthrough

Development of Prophylactic Strategies

Abandoned and Emerging Approaches

Controversies and Guideline Disagreement

Complications

Systemic and Renal Sequelae

Portal Hypertensive Complications

Complication Summary Table

Iatrogenic and Medication-Related Risks

Prognosis & Natural History

Mortality and Recurrence Dynamics

Predictors of Poor Outcome

Impact of Prophylaxis on Survival

Special Populations & Pregnancy

Step 1: Diagnostic and Therapeutic